CUMULATIVE SUPPLEMENT 10

JAN'91-OCT'91



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

Cumulative Supplement

October 1991

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

CUMULATIVE SUPPLEMENT 10

OCTOBER 1991

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 11th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Division of Blood and Blood Products and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (⌑) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∋ " symbol to designate their non-marketed status. All products having a " ∋ " symbol in the 12th Cumulative Supplement of the 11th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 12th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 CHANGE OF A THERAPEUTIC EQUIVALENCY CODE FOR A DRUG ENTITY

Methylphenidate Hydrochloride:

In its initial considerations, the Agency did not classify methylphenidate hydrochloride (MPD) as having an actual or potential bioequivalence problem (42 FR 1624, January 7, 1977). MPD in oral tablet form (Ritalin™, manufactured by Ciba Pharmaceuticals) is a DESI drug product that was raised to the effective status on October 7, 1970 (35 FR 15771). MPD in tablet form remained single source until December 23, 1977 when it became available from MD Pharmaceutical. In the first and subsequent editions of the "Orange Book" this drug product has been coded coded **AA**.

Recently, FDA's Therapeutic Inequivalence Action Coordination Committee (TIACC) investigated a report from the Kaiser Permanente Medical Care Program in Oakland, California, suggesting therapeutic inequivalence regarding duration of action in a marketed lot of MD Pharmaceutical MPD tablets. Samples from MD Pharmaceutical and Ciba were tested in accordance with USP dissolution test procedures by an FDA field laboratory. Although both products met the single point USP criteria of not less than 75% of the labeled amount of MPD dissolved within 45 minutes, the dissolution profile of the MD Pharmaceutical product was much faster than that of the Ciba product.

Based on these in vitro dissolution data, FDA commissioned an in- vivo bioequivalence study under its extramural contract research program. The bioequivalence study indicated that at one-half and three-fourths hours after administration of a single 20 mg dose, somewhat more of MD Pharmaceutical's product had been absorbed compared to Ciba's Ritalin. However, the MD Pharmaceutical MPD 20 mg tablets met FDA's criteria for rate and extent of absorbtion, and were considered to be bioequivalent to Ciba's Ritalin 20 mg tablets.

Because of the in vitro dissolution data coupled with new information discovered during the course of this evaluation, the FDA has proposed a change in the therapeutic equivalence code from **AA** to **BP** for listed MPD tablets. This change requires that firms submitting an ANDA for MPD tablets submit an acceptable in vivo bioequivalence study to gain approval in addition to submission of all previously required information.

Agency reasons for considering this change in the equivalence code is as follows:

1) Although early work suggested that MPD tablets are completely absorbed recent studies utilizing more specific techniques calculated the relative bioavailability to be 11 to 53%. (Chan et al: Pediatrics, **72**, 56-59, 1983). This raised concerns regarding possible approval of a superbioavailable drug product.

2) The current dl-MPD pharmacological activity derives primarily from the d isomer which may exhibit non-linear kinetics. (Srinivas et al: Journal of Pharmacology and Experimental Therapeutics, **241**, 300-306, 1987).

3) The previously cited in vitro dissolution data suggesting that substantial differences in in vitro dissolution may exist between different formulations of MPD.

The Agency invites written comments and scientific data regarding the Agency's proposal to change the therapeutic equivalence code for listed MPD oral tablets from AA to **BP**. The comment period will be 60 days from the first day in the monthly Supplement.

1.4 THE B* THERAPEUTIC EQUIVALENCE CODE

Drug products requiring further FDA investigation and review to determine therapeutic equivalence.

The code **B*** is assigned to products that were previously assigned an **A** code if FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

1.5 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
CORD LABORATORIES INC	GENEVA PHARMACEUTICALS INC	GENEVA
GIST BROCADES	BROCADES PHARMA bv	BROCADES PHARMA
ICI PHARMACEUTICALS PR INC	IPR PHARMACEUTICALS INC	IPR
KENDALL MCGAW PHARMACEUTICALS	GENSIA PHARMACEUTICALS INC	GENSIA
PHARMACIA LABORATORIES DIV PHARMACIA INC	KABI PHARMACIA	KABI
REID ROWELL INC	SOLVAY PHARMACEUTICALS	SOLVAY

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1990) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1990	MAR 1991	JUN 1991	SEP 1991
DRUG PRODUCTS LISTED	10123	9953	9900	9869
SINGLE SOURCE	2030 (20.1%)	2090 (21.0%)	2110 (21.3%)	2103 (21.4%)
MULTISOURCE	8093 (79.9%)	7863 (79.0%)	7790 (78.7%)	7766 (78.6%)
THERAPEUTICALLY EQUIVALENT	7222 (71.3%)	7061 (71.0%)	6937 (70.1%)	6914 (70.0%)
NOT THERAPEUTICALLY EQUIVALENT	752 (7.4%)	660 (6.6%)	702 (7.1%)	706 (7.2%)
EXCEPTIONS[1]	119 (1.2%)	142 (1.4%)	151 (1.5%)	146 (1.4%)
NEW MOLECULAR ENTITIES APPROVED	--	5	4	3
NUMBER OF APPLICANTS	400	408	417	418

[1]Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

	PROVAL #3			
/AA/	/SOLVAY/	325MG;30MG		/N85685/001/
	ə SOLVAY	325MG;30MG		N85685 001
	TYLENOL W/ CODEINE NO. 3			
/AA/	/JOHNSON/RW/	300MG;30MG		/N87422/001/
	ə JOHNSON RW	300MG;30MG		N87422 001
	TYLENOL W/ CODEINE NO. 4			
	/JOHNSON/RW/	300MG;60MG		/N87421/001/
	ə JOHNSON RW	300MG;60MG		N87421 001

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
	MIKART	650MG;60MG¤		N89363 001 SEP 25, 1991
	ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2			
/AA/	/AM THERAP/	300MG;15MG		/N89481/001/ /MAR 03, 1987/
	ə AM THERAP	300MG;15MG		N89481 001 MAR 03, 1987
	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
> DLT >/AA/	/PARKE/DAVIS/	300MG;60MG		/N87306/001/
> ADD >	ə WARNER CHILCOTT	300MG;60MG		N87306 001
	TYLENOL W/ CODEINE			
/AA/	/JOHNSON/RW/	325MG;15MG		/N85056/002/
/AA/		325MG;30MG		/N85056/003/
		325MG;7.5MG		/N85056/001/
		325MG;60MG		/N85056/004/
	ə JOHNSON RW	325MG;7.5MG		N85056 001
	ə	325MG;15MG		N85056 002
	ə	325MG;30MG		N85056 003
	ə	325MG;60MG		N85056 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MIKART	500MG;2.5MG		N89698 001 AUG 25, 1989
AA		500MG;7.5MG		N89699 001 AUG 25, 1989
		500MG;2.5MG		/N89698/001/ /AUG/25,/1989/
		500MG;7.5MG		/N89699/001/ /AUG/25,/1989/
/AA/	/PHARM/BASICS/	500MG;5MG		/N89291/001/ /MAY/29,/1987/
B*	PHARM BASICS	500MG;5MG		N89291 001 MAY 29, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	WATSON	500MG;2.5MG¤		N81079 001 AUG 30, 1991
AA		500MG;7.5MG¤		N81080 001 AUG 30, 1991
AA		750MG;7.5MG¤		N81083 001 AUG 30, 1991
	VICODIN ES			
AA	KNOLL	750MG;7.5MG		N89736 001 DEC 09, 1988
		750MG;7.5MG		/N89736/001/ /DEC/09,/1988/

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	TYLOX-325			
	/JOHNSON/RW/	325MG;5MG		/N88246/001/ /NOV/08,/1984/
	ə JOHNSON RW	325MG;5MG		N88246 001 NOV 08, 1984

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
> DLT >/AB/	/BOLAR/	325MG;50MG		/N70398/001/ /DEC/18,/1986/
> DLT >				
> DLT >/AB/		650MG;100MG		/N70399/001/ /DEC/18,/1986/
> DLT >				
> ADD >	ə BOLAR	325MG;50MG		N70398 001 DEC 18, 1986
> ADD >				
> ADD >	ə	650MG;100MG		N70399 001 DEC 18, 1986
> ADD >				
/AB/	/CHELSEA/	325MG;50MG		/N71336/001/ /DEC/11,/1986/
/AB/		650MG;100MG		/N71337/001/ /DEC/11,/1986/
B*	CHELSEA	325MG;50MG		N71336 001 DEC 11, 1986
B*		650MG;100MG		N71337 001 DEC 11, 1986

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

	∂ ALRA	250MG	N83320 001	
	/∂/BANMAX/	/250MG/	/N83320/001/	
>DLT >/AB/	/BOLAR/	/250MG/	/N84498/002/	
>ADD >	∂ BOLAR	250MG	N84498 002	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

/DR'LEX/

/AT/	/NORWICH/EATON/	/2%/	/N86845/001/	
	∂ NORWICH EATON	2%	N86845 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

/DR'LEX 'HC/

/AT/	/NORWICH/EATON/	/2%;1%/	/N86844/001/	
	∂ NORWICH EATON	2%;1%	N86844 001	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

/AB/	/PHARM/BASICS/	/250MG/	/N70753/001/	
/AB/		/500MG/	/NOV/03,/1986/ /N70754/001/ /NOV/03,/1986/	
B*	PHARM BASICS	250MG	N70753 001 NOV 03, 1986	
B*		500MG	N70754 001 NOV 03, 1986	

ACETOPHENAZINE MALEATE

/TABLET;/ORAL/

/TINDAL/

/BP/	/SCHERING/	/20MG/	/N12254/002/	
	∂ SCHERING	20MG	N12254 002	

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

	BURROUGHS WELLCOME	400MG*	N20089 001 APR 30, 1991	
		800MG*	N20089 002 APR 30, 1991	

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

AB	DANBURY	EQ 2MG BASE*	N72629 001 JAN 31, 1991	
AB		EQ 4MG BASE*	N72630 001 JAN 31, 1991	
AB	MYLAN	EQ 2MG BASE*	N72893 001 JAN 17, 1991	
AB		EQ 4MG BASE*	N72894 001 JAN 17, 1991	
AB	WATSON	EQ 2MG BASE*	N72764 001 AUG 28, 1991	
AB		EQ 4MG BASE*	N72765 001 AUG 28, 1991	

ALCOHOL

INJECTABLE; INJECTION

/ALCOHOL 5% IN DEXTROSE 5%/

/AP/	/CUTTER/	/5ML/100ML/	/N83483/001/	
	∂ CUTTER	5ML/100ML	N83483 001	

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

	GENZYME	80 UNITS/ML*	N20057 003 APR 05, 1991	

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

/AB/	/BOLAR/	/300MG/	/N18241/002/ /NOV/16,/1984/	
	∂ BOLAR	300MG	N18241 002 NOV 16, 1984	

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

/AB/	/PUREPAC/	/100MG/	/N70579/001/ /APR/14,/1986/	
/AB/		/300MG/	/N70580/001/ /APR/14,/1986/	
	∂ PUREPAC	100MG	N70579 001 APR 14, 1986	
	∂	300MG	N70580 001 APR 14, 1986	

ALPRAZOLAM

TABLET; ORAL

XANAX

/∂/UPJOHN/	/2MG/	/N18276/004/ /NOV/27,/1985/	
UPJOHN	2MG	N18276 004 NOV 27, 1985	

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

AA	COPLEY	50MG/5ML*	N73115 001 AUG 23, 1991	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

>ADD>	AB	MYLAN	5MG;50MG*	N73209 001 OCT 31, 1991	
>ADD>	AB	ROYCE	5MG;50MG*	N73334 001 JUL 19, 1991	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

/AP/	/INTL MEDICATION/	/25MG/ML/	/N87867/001/ /NOV/10,/1983/	
/AP/		/25MG/ML/	/N87868/001/ /NOV/10,/1983/	
	∂ INTL MEDICATION	25MG/ML	N87867 001 NOV 10, 1983	
	∂	25MG/ML	N87868 001 NOV 10, 1983	
/AP/	/SOLOPAK/	/25MG/ML/	/N88429/001/ /MAY/30,/1985/	
	∂ SOLOPAK	25MG/ML	N88429 001 MAY 30, 1985	

TABLET; ORAL

AMINOPHYLLINE

>ADD>	BD	LANNETT	100MG	N84588 001
>ADD>	BD		200MG	N84588 002
>DLT>	/∂/		/100MG/	/N84588/001/
>DLT>	/∂/		/200MG/	/N84588/002/

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

/AMITID/

/AB/	/SQUIBB/	/10MG/	/N86454/001/	
/AB/		/25MG/	/N86454/002/	
/AB/		/50MG/	/N86454/003/	
/AB/		/75MG/	/N86454/004/	
/AB/		/100MG/	/N86454/005/	
	∂ SQUIBB	10MG	N86454 001	
	∂	25MG	N86454 002	
	∂	50MG	N86454 003	
	∂	75MG	N86454 004	
	∂	100MG	N86454 005	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	GENSIA	25MG/ML*	N81142 001 SEP 25, 1991	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

>DLT >/AB/	/BARR/	/10MG/	/N85744/001/	
>DLT >/AB/		/25MG/	/N85627/001/	
>DLT >/AB/		/50MG/	/N85745/001/	
>DLT >/AB/		/75MG/	/N85743/001/	
>DLT >/AB/		/100MG/	/N85742/002/	
>DLT >			/MAY/11,/1982/	
>DLT >/AB/		/150MG/	/N89423/001/	
>DLT >			/FEB/17,/1987/	
>ADD >	ə BARR	10MG	N85744 001	
>ADD >	ə	25MG	N85627 001	
>ADD >	ə	50MG	N85745 001	
>ADD >	ə	75MG	N85743 001	
>ADD >	ə	100MG	N85742 002	
>ADD >			MAY 11, 1982	
>ADD >	ə	150MG	N89423 001	
>ADD >			FEB 17, 1987	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

/AB/	/PHARM/BASICS/	/EQ 12.5MG BASE;5MG/	/N70477/001/
			/JAN/12,/1988/
/AB/		/EQ 25MG BASE;10MG/	/N70478/001/
			/JAN/12,/1988/
B*	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001
			JAN 12, 1988
B*		EQ 25MG BASE;10MG	N70478 001
			JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

>DLT >/AB/	/BOLAR/	/10MG;2MG/	/N70373/001/
>DLT >			/AUG/25,/1986/
>DLT >/AB/		/10MG;4MG/	/N70375/001/
>DLT >			/AUG/25,/1986/
>DLT >/AB/		/25MG;2MG/	/N70374/001/
>DLT >			/AUG/25,/1986/
>DLT >/AB/		/25MG;4MG/	/N70376/001/
>DLT >			/AUG/25,/1986/
>DLT >/AB/		/50MG;4MG/	/N70377/001/
>DLT >			/NOV/04,/1986/
>ADD >	ə BOLAR	10MG;2MG	N70373 001
>ADD >			AUG 25, 1986
>ADD >	ə	10MG;4MG	N70375 001
>ADD >			AUG 25, 1986
>ADD >	ə	25MG;2MG	N70374 001
>ADD >			AUG 25, 1986
>ADD >	ə	25MG;4MG	N70376 001
>ADD >			AUG 25, 1986
>ADD >	ə	50MG;4MG	N70377 001
>ADD >			NOV 04, 1986
/AB/	/CHELSEA/	/10MG;2MG/	/N71384/001/
			/NOV/03,/1986/
/AB/		/10MG;4MG/	/N71386/001/
			/NOV/03,/1986/
/AB/		/25MG;2MG/	/N71385/001/
			/NOV/03,/1986/
/AB/		/25MG;4MG/	/N71387/001/
			/NOV/03,/1986/
B*	CHELSEA	10MG;2MG	N71384 001
			NOV 03, 1986
B*		10MG;4MG	N71386 001
			NOV 03, 1986
B*		25MG;2MG	N71385 001
			NOV 03, 1986
B*		25MG;4MG	N71387 001
			NOV 03, 1986
/B*/		/50MG;4MG¤/	/N71558/001/
			/MAR/02,/1987/
	ə	50MG;4MG¤	N71558 001
			MAR 02, 1987
>ADD > AB	ROYCE	10MG;2MG¤	N73007 001
>ADD >			OCT 17, 1991
>ADD > AB		10MG;4MG¤	N73009 001
>ADD >			OCT 17, 1991
>ADD > AB		25MG;2MG¤	N73008 001
>ADD >			OCT 17, 1991
>ADD > AB		25MG;4MG¤	N73010 001
>ADD >			OCT 17, 1991

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	GENEVA	25MG¤	N72943 001 JUN 28, 1991
AB		50MG¤	N72944 001 JUN 28, 1991
AB		100MG¤	N72878 001 JUN 28, 1991
AB		150MG¤	N72879 001 JUN 28, 1991

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

/AP/	/INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62634/002/ /JAN/09,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62634/003/ /JAN/09,/1987/
	ə INTL MEDICATION	EQ 1GM BASE/VIAL	N62634 002 JAN 09, 1987
	ə	EQ 2GM BASE/VIAL	N62634 003 JAN 09, 1987

POLYCILLIN-N

AP	BRISTOL	EQ 10GM BASE/VIAL	N61395 006

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
/PENBRITIN/

>DLT>				
>DLT>/AB/	/WYETH/AYERST/	/EQ 250MG BASE/	/N60908/001/
>DLT>/AB/		/EQ 500MG BASE/	/N60908/002/
>ADD>	ə WYETH AYERST	EQ 250MG BASE	N60908 001
>ADD>	ə	EQ 500MG BASE	N60908 002

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M,V,I,-12 LYOPHILIZED

/AP/	/ARMOUR/	/100MG/VIAL;0.06MG/VIAL;/ /0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;/ /0.4MG/VIAL;40MG/VIAL;4MG/VIAL;/ /3.6MG/VIAL;3MG/VIAL;1MG/VIAL;/ /10MG/VIAL/	/N18933/002/ /AUG/08,/1985/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M,V,I,-12 LYOPHILIZED

AP	ASTRA	100MG/VIAL;0.06MG/VIAL; 0.005MG/VIAL;15MG/VIAL;5UGM/VIAL; 0.4MG/VIAL;40MG/VIAL;4MG/VIAL; 3.6MG/VIAL;3MG/VIAL;1MG/VIAL; 10MG/VIAL	N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
MVC PLUS

/AP/	/ASCOT/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS /ML;1 IU/ML/	/N18439/002/ /AUG/08,/1985/
AP	STERIS	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS /ML;1 IU/ML	N18439 002 AUG 08, 1985

ASPIRIN; BUTALBITAL; CAPSULE

CAPSULE; ORAL
/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86231 002 FEB 12, 1985

TABLET; ORAL
/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86237/002/ /MAR/23,/1984/

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86237 002 MAR 23, 1984

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC
B* PAR 385MG;30MG;25MG N71642 001 JUN 23, 1987
/BX/ /385MG;30MG;25MG/ /N71642/001/ /JUN/23,/1987/

ORPHENGESIC FORTE
B* PAR 770MG;60MG;50MG N71643 001 JUN 23, 1987
/BX/ /770MG;60MG;50MG/ /N71643/001/ /JUN/23,/1987/

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
COMPOUND 65
∂ ALRA 389MG;32.4MG;65MG N84553 002 AUG 17, 1983
/∂/BANMAX/ /389MG;32.4MG;65MG/ /N84553/002/ /AUG/17,/1983/

ASPIRIN; CARISOPRODOL

TABLET; ORAL
>DLT> /CARISOPRODOL COMPOUND/
>DLT>/AB/ /BOLAR/ /325MG;200MG/ /N88809/001/ /OCT/03,/1985/
>DLT>
>ADD> ∂ BOLAR 325MG;200MG N88809 001 OCT 03, 1985
>ADD>

ATENOLOL

TABLET; ORAL
ATENOLOL
AB COPLEY 50MG¤ N73025 001 SEP 17, 1991
AB 100MG¤ N73026 001 SEP 17, 1991

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
>DLT>/AA/ /HEATHER/ /0.025MG;2.5MG/ /N86798/001/
>ADD> ∂ HEATHER 0.025MG;2.5MG N86798 001
/LONOXATE/
/AA/ /CORD/ /0.025MG;2.5MG/ /N85311/002/

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LONOX
AA CORD 0.025MG;2.5MG N85311 002

BACLOFEN

TABLET; ORAL
BACLOFEN
AB DANBURY 10MG¤ N72824 001 SEP 18, 1991
AB 20MG¤ N72825 001 SEP 18, 1991
/AB/ /PHARM/BASICS/ /10MG/ /N71260/001/ /MAY/06,/1988/
/AB/ /20MG/ /N71261/001/ /MAY/06,/1988/
B* PHARM BASICS 10MG N71260 001 MAY 06, 1988
B* 20MG N71261 001 MAY 06, 1988

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
LOTENSIN
CIBA
EQ 5MG BASE¤ N19851 001 JUN 25, 1991
EQ 10MG BASE¤ N19851 002 JUN 25, 1991
EQ 20MG BASE¤ N19851 003 JUN 25, 1991
EQ 40MG BASE¤ N19851 004 JUN 25, 1991

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

> DLT >	/AA/	/HEATHER/	/0.025MG;2.5MG/	/N86798/001/
> ADD >		@ HEATHER	0.025MG;2.5MG	N86798 001
		/LONGVATE/		
	/AA/	/CORD/	/0.025MG;2.5MG/	/N85311/002/

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

/AA/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/AA/		/1MG/	/N89212/001/ /JUN/14,/1988/
/AA/		/2MG/	/N89213/001/ /JUN/14,/1988/
B*	PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
B*		1MG	N89212 001 JUN 14, 1988
B*		2MG	N89213 001 JUN 14, 1988

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

ROSS	25MG/ML	N20032 001 JUL 01, 1991

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

> DLT >	/AA/	/BOLAR/	/5MG/	/N85230/002/
> DLT >	/AA/		/10MG/	/N85228/001/
> DLT >	/AA/		/25MG/	/N85229/001/
> DLT >	/AA/		/50MG/	/N87397/001/
> ADD >		@ BOLAR	5MG	N85230 002
> ADD >		@	10MG	N85228 001
> ADD >		@	25MG	N85229 001
> ADD >		@	50MG	N87397 001

DUVOID

/AA/	/NORWICH/EATON/	/10MG/	/N86262/001/
/AA/		/25MG/	/N85882/002/
/AA/		/25MG/	/N86263/001/
/AA/		/50MG/	/N85882/003/
AA	ROBERTS	10MG	N86262 001
AA		25MG	N86263 001
AA		50MG	N85882 003

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

/ABBOTT/	/800MG/100ML/	/N19008/001/ /APR/16,/1986/
@ ABBOTT	800MG/100ML	N19008 001 APR 16, 1986

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AA/	/PAR/	/4MG/	/N87009/001/
	@ PAR	4MG	N87009 001
/AA/	/VITARINE/	/4MG/	/N85850/001/
	@ VITARINE	4MG	N85850 001

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

/ELIXIR;/ORAL/

/BIPHETAP/

/PHARM/BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/ /SEP/26,/1984/
@ PHARM BASICS	4MG/5ML;25MG/5ML	N88687 001 SEP 26, 1984

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

/NORWICH/EATON/	/EQ/0.3MG/BASE/ML/	/N18401/001/
R AND C	EQ 0.3MG BASE/ML	N18401 001

BUPROPION HYDROCHLORIDE

TABLET; ORAL

WELLBUTRIN

/BURROUGHS/WELLCOME/	/50MG/	/N18644/001/ /DEC/30,/1985/
@ BURROUGHS WELLCOME	50MG	N18644 001 DEC 30, 1985

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM

/AA/	/CORD/	/15MG/	/N84292/003/ /FEB/09/1982/	
/AA/		/30MG/	/N84272/002/	
	ə CORD	15MG	N84292 003 FEB 09, 1982	
	ə	30MG	N84272 002	
/AA/	/WHITE/TOWNE/PAULSEN/	/15MG/	/N83325/002/	
	ə WHITE TOWNE PAULSEN	15MG	N83325 002	

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR

AP	RHONE POULENC RORER	200 IU/ML	N17769 001

MIACALCIN

AP	SANDOZ	200 IU/ML¤	N17808 002 MAR 29, 1991

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/
/ACETATED/RINGER'S/IN/PLASTIC/CONTAINER/

/MCGAW/	/20MG/100ML;30MG/100ML;380MG/100ML;/ /600MG/100ML/	/N18725/001/ /NOV/29/1982/	
ə MCGAW	20MG/100ML;30MG/100ML;380MG/100ML; 600MG/100ML	N18725 001 NOV 29, 1982	

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

/AP/	/ABBOTT/	/EQ 90MG CALCIUM/5ML/	/N83159/001/
	ə ABBOTT	EQ 90MG CALCIUM/5ML	N83159 001

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

/AB/	/PHARM/BASICS/	/200MG/	/N70300/001/ /MAY/15/1986/
B*	PHARM BASICS	200MG	N70300 001 MAY 15, 1986

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

	MSD	50MG;200MG¤	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

/AA/	/BOLAR/	/350MG/	/N85433/001/
	ə BOLAR	350MG	N85433 001
>ADD> AA	MUTUAL PHARM	350MG¤	N89346 001 OCT 17, 1991
>ADD>			

CEFADROXIL

CAPSULE; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 500MG BASE/	/N62378/001/ /MAR/16/1982/
	ə BRISTOL	EQ 500MG BASE	N62378 001 MAR 16, 1982

POWDER FOR RECONSTITUTION; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N62376/001/ /MAR/16/1982/
/AB/		/EQ 250MG BASE/5ML/	/N62376/002/ /MAR/16/1982/
/AB/		/EQ 500MG BASE/5ML/	/N62376/003/ /MAR/16/1982/
	ə BRISTOL	EQ 125MG BASE/5ML	N62376 001 MAR 16, 1982
	ə	EQ 250MG BASE/5ML	N62376 002 MAR 16, 1982
	ə	EQ 500MG BASE/5ML	N62376 003 MAR 16, 1982

TABLET; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 1GM BASE/	/N62408/001/ /AUG/31/1982/
	ə BRISTOL	EQ 1GM BASE	N62408 001 AUG 31, 1982

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF IN PLASTIC CONTAINER

	BAXTER	EQ 10MG BASE/ML¤	N63002 001 MAR 28, 1991
		EQ 20MG BASE/ML¤	N63002 002 MAR 28, 1991

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

CEPHALEXIN

AB	SQUIBB MARK	EQ 125MG BASE/5ML¤	N62986 001 APR 18, 1991

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

/AP/	/INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62426/002/ /MAY/03,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62426/003/ /MAY/03,/1985/
/AP/		/EQ 4GM BASE/VIAL/	/N62426/004/ /MAY/03,/1985/
		/EQ/500MG/BASE/VIAL/	/N62426/001/ /MAY/03,/1985/
	∂ INTL MEDICATION	EQ 500MG BASE/VIAL	N62426 001 MAY 03, 1985
	∂	EQ 1GM BASE/VIAL	N62426 002 MAY 03, 1985
	∂	EQ 2GM BASE/VIAL	N62426 003 MAY 03, 1985
	∂	EQ 4GM BASE/VIAL	N62426 004 MAY 03, 1985

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

>ADD>	BAXTER	EQ 20MG BASE/ML¤	N62422 005 JUL 16, 1991
>ADD>		EQ 40MG BASE/ML¤	N62422 006 JUL 16, 1991

CEPHRADINE

CAPSULE; ORAL

VELOSEF 250

/AB/	/ERSANA/	/250MG/	/N50548/001/
	∂ ERSANA	250MG	N50548 001

CEPHRADINE

CAPSULE; ORAL

VELOSEF 500

/AB/	/ERSANA/	/500MG/	/N50548/002/
	∂ ERSANA	500MG	N50548 002

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/SUPERPHARM/	/5MG/	/N88987/001/ /APR/25,/1985/
/AB/		/10MG/	/N88986/001/ /APR/25,/1985/
/AB/		/25MG/	/N88988/001/ /APR/25,/1985/
	∂ SUPERPHARM	5MG	N88987 001 APR 25, 1985
	∂	10MG	N88986 001 APR 25, 1985
	∂	25MG	N88988 001 APR 25, 1985

LYGEN

∂ ALRA	5MG	N85107 001
∂	10MG	N85009 001
∂	25MG	N85108 001
/∂/BANMAX/	/5MG/	/N85107/001/
/∂/	/10MG/	/N85009/001/
/∂/	/25MG/	/N85108/001/

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

>DLT>/AB/	/BOLAR/	/250MG/	/N85165/001/
>DLT>/AB/		/500MG/	/N84026/001/ /SEP/01,/1982/
>DLT>			
>ADD>	∂ BOLAR	250MG	N85165 001
>ADD>	∂	500MG	N84026 001 SEP 01, 1982
>ADD>			
/B*/	/CHELSEA/	/500MG¤/	/N86796/001/ /AUG/15,/1983/
	∂ CHELSEA	500MG¤	N86796 001 AUG 15, 1983

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

/CHLOROTHIAZIDE/W//RESERPINE/

> DLT >	/BP/	/BOLAR/	/500MG;0.125MG/	/N88151/001/	
> DLT >				/JUN/09,/1983/	
> DLT >					
> ADD >		@ BOLAR	500MG;0.125MG	N88151 001	
> ADD >				JUN 09, 1983	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

/AP/	/LEMMON/	/10MG/ML/	/N83593/001/	
AP	STERIS	10MG/ML	N83593 001	

TABLET; ORAL

/ANTAGONATE/

/AA/	/MILES/	/4MG/	/N83381/001/	
	@ MILES	4MG	N83381 001	

CHLORPHENIRAMINE MALEATE

/AA/	/VITARINE/	/4MG/	/N85837/001/	
	@ VITARINE	4MG	N85837 001	

/PHENETRON/

/AA/	/LANNETT/	/4MG/	/N80846/001/	
	@ LANNETT	4MG	N80846 001	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N85591/001/	
AP	STERIS	25MG/ML	N85591 001	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

> DLT >	/AB/	/BOLAR/	/100MG/	/N88608/001/	
> DLT >				/APR/12,/1984/	
> DLT >	/AB/		/250MG/	/N88568/001/	
> DLT >				/APR/12,/1984/	
> ADD >		@ BOLAR	100MG	N88608 001	
> ADD >				APR 12, 1984	
> ADD >		@	250MG	N88568 001	
> ADD >				APR 12, 1984	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

/AB/	/PHARM/BASICS/	/100MG/	/N88708/001/		
			/AUG/30,/1984/		
/AB/		/250MG/	/N88709/001/		
			/AUG/30,/1984/		
B*	PHARM BASICS	100MG	N88708 001		
			AUG 30, 1984		
B*		250MG	N88709 001		
			AUG 30, 1984		

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

> DLT >	/AA/	/BOLAR/	/25MG/	/N87050/001/	
> DLT >	/AB/		/50MG/	/N87029/001/	
> ADD >		@ BOLAR	25MG	N87050 001	
> ADD >		@	50MG	N87029 001	
	/AB/	/SUPERPHARM/	/25MG/	/N87473/001/	
				/FEB/09,/1983/	
		@ SUPERPHARM	25MG	N87473 001	
				FEB 09, 1983	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	DANBURY	500MG¤	N81019 001	
			JUL 29, 1991	

> ADD > CLARITHROMYCIN

> ADD > TABLET; ORAL

> ADD > BIAXIN

> ADD > ABBOTT

> ADD >	250MG¤	N50662 001	
> ADD >		OCT 31, 1991	
> ADD >	500MG¤	N50662 002	
> ADD >		OCT 31, 1991	

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST D

> DLT >	/DORSEY/	/EQ/1MG/BASE;75MG/	/N18298/001/	
> DLT >			/DEC/15,/1982/	

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST D

>ADD>	SANDOZ	EQ 1MG BASE;75MG	N18298 001 DEC 15, 1982	>DLT>/AB/
>ADD>				>DLT>

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB	DANBURY	EQ 75MG BASE¤	N63082 001 JUL 31, 1991	>ADD>
AB		EQ 150MG BASE¤	N63083 001 JUL 31, 1991	>ADD>

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

/AP/	/LEMMON/	/EQ 150MG BASE/ML/	/N62900/001/ /JUN/08,/1988/	>DLT>/AB/
/AP/		/EQ 150MG BASE/ML/	/N63079/001/ /MAR/05,/1990/	>DLT>
AP	STERIS	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988	>ADD>
AP		EQ 150MG BASE/ML	N63079 001 MAR 05, 1990	>ADD>

CLIOQUINOL; HYDROCORTISONE

CREAM; TOPICAL

VIOFORM-HYDROCORTISONE

CIBA	3%;0.5%	N10412 002	/AB/
	3%;1%	N10412 001	/AB/

OINTMENT; TOPICAL

VIOFORM-HYDROCORTISONE

ə CIBA	3%;0.5%	N10412 004	B*
	3%;1%	N10412 003	B*

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

AB	NOVOPHARM	500MG¤	N72600 001 JUL 25, 1991	/AB/ /PUREPAC/ /3.75MG/
				ə PUREPAC 3.75MG

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL

>DLT>/AB/	/BOLAR/	/0.1MG/	/N70395/001/ /MAR/23,/1987/	>ADD>
>DLT>				>ADD>
>DLT>/AB/		/0.2MG/	/N70396/001/ /MAR/23,/1987/	>ADD>
>DLT>				>ADD>
>DLT>/AB/		/0.3MG/	/N70397/001/ /MAR/23,/1987/	>ADD>
>DLT>				>ADD>
>ADD>	ə BOLAR	0.1MG	N70395 001 MAR 23, 1987	>DLT>/AB/
>ADD>				>DLT>
>ADD>	ə	0.2MG	N70396 001 MAR 23, 1987	>DLT>/AB/
>ADD>				>DLT>
>ADD>	ə	0.3MG	N70397 001 MAR 23, 1987	/AB/
>ADD>				>DLT>/AB/
>DLT>/AB/	/DURAMED/	/0.1MG/	/N71103/001/ /AUG/14,/1986/	>DLT>
>DLT>				>ADD>
/AB/		/0.2MG/	/N71102/001/ /AUG/14,/1986/	>ADD>
>DLT>/AB/		/0.3MG/	/N71101/001/ /AUG/14,/1986/	ə DURAMED 0.1MG
>DLT>				AUG 14, 1986
>ADD>	ə DURAMED	0.1MG	N71103 001 AUG 14, 1986	N71102 001
>ADD>				AUG 14, 1986
ə		0.2MG	N71102 001 AUG 14, 1986	ə 0.3MG N71101 001
>ADD>	ə	0.3MG	N71101 001 AUG 14, 1986	AUG 14, 1986
>ADD>				

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

/AB/	/PHARM/BASICS/	/3.75MG/	/N71242/001/ /MAY/20,/1987/
/AB/		/7.5MG/	/N71243/001/ /MAY/20,/1987/
/AB/		/15MG/	/N71244/001/ /MAY/20,/1987/
B*	PHARM BASICS	3.75MG	N71242 001 MAY 20, 1987
B*		7.5MG	N71243 001 MAY 20, 1987
B*		15MG	N71244 001 MAY 20, 1987
/AB/	/PUREPAC/	/3.75MG/	/N71924/001/ /APR/25,/1988/
	ə PUREPAC	3.75MG	N71924 001 APR 25, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/SEARLE/	/3.75MG/	/N71727/001/	/DEC/18,/1987/
/AB/		/7.5MG/	/N71728/001/	/DEC/18,/1987/
/AB/		/15MG/	/N71729/001/	/DEC/18,/1987/
	ə SEARLE	3.75MG	N71727 001	DEC 18, 1987
	ə	7.5MG	N71728 001	DEC 18, 1987
	ə	15MG	N71729 001	DEC 18, 1987

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/AM/THERAP/	/3.75MG/	/N71747/001/	/JUN/09,/1987/
/AB/		/7.5MG/	/N71748/001/	/JUN/09,/1987/
/AB/		/15MG/	/N71749/001/	/JUN/09,/1987/
	ə AM THERAP	3.75MG	N71747 001	JUN 09, 1987
	ə	7.5MG	N71748 001	JUN 09, 1987
	ə	15MG	N71749 001	JUN 09, 1987

CLOTRIMAZOLE

CREAM; VAGINAL
/GYNE-LOTRIMIN/

/AT/	/SCHERING/	/1%/	/N18052/001/

TABLET; VAGINAL
/GYNE-LOTRIMIN/

/AT/	/SCHERING/	/100MG/	/N17717/001/

COLCHICINE; PROBENECID

TABLET; ORAL

>DLT>	/PROBENECID/W//COLCHICINE/			
>DLT>	/BP/ /BOLAR/	/0.5MG;500MG/	/N83221/001/	
>ADD>	ə BOLAR	0.5MG;500MG	N83221 001	

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTISONE ACETATE

/BP/	/LEMMON/	/25MG/ML/	/N85677/001/
/BP/		/50MG/ML/	/N85677/002/
BP	STERIS	25MG/ML	N85677 001
BP		50MG/ML	N85677 002

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE

/AP/	/LEMMON/	/0.1MG/ML/	/N83013/001/
/AP/		/1MG/ML/	/N83064/001/
AP	STERIS	0.1MG/ML	N83013 001
AP		1MG/ML	N83064 001

CYANOCOBALAMIN

	AKORN	1MG/ML	N87969 001 NOV 10, 1983
/AP/	/LEMMON/	/0.1MG/ML/	/N83120/001/
/AP/		/1MG/ML/	/N83120/002/
/AP/	/LYPHOMED/	/0.03MG/ML/	/N80516/003/
/AP/		/0.1MG/ML/	/N80516/001/
/AP/		/1MG/ML/	/N80516/002/
	ə LYPHOMED	0.03MG/ML	N80510 003
	ə	0.1MG/ML	N80510 001
	ə	1MG/ML	N80510 002
AP	STERIS	0.1MG/ML	N83120 001
AP		1MG/ML	N83120 002

/DODECAMIN/

/AP/	/AKORN/	/1MG/ML/	/N87969/001/ /NOV/16,/1983/

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	MYLAN	10MG	N73144 001 MAY 31, 1991

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AK-PENTOLATE

AT	AKORN	1%	N85555 001

/CYCLOPENTOLATE HCL/

/AT/	/AKORN/	/1%/	/N85555/001/

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CYCLOPENTOLATE HCL		
AT	STERIS	1%	N89162 001 JAN 24, 1991

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

	CYPROHEPTADINE HCL		
/AA/	/NASKA/	/2MG/5ML/	/N89021/001/ /DEC/21,/1987/
@	NASKA	2MG/5ML	N89021 001 DEC 21, 1987

TABLET; ORAL

	CYPROHEPTADINE HCL		
>DLT>/AA/	/BOLAR/	/4MG/	/N85245/001/
>ADD> @	BOLAR	4MG	N85245 001

DANAZOL

CAPSULE; ORAL

	DANAZOL		
/AB/	/AM THERAP/	/200MG/	/N71569/001/ /DEC/30,/1987/
B*	AM THERAP	200MG	N71569 001 DEC 30, 1987

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

	ENDURONYL		
>DLT> /BP/	/ABBOTT/	/0.25MG;5MG/	/N12775/001/
>ADD>	ABBOTT	0.25MG;5MG	N12775 001
	ENDURONYL FORTE		
>DLT> /BP/	/ABBOTT/	/0.5MG;5MG/	/N12775/002/
>ADD>	ABBOTT	0.5MG;5MG	N12775 002
>DLT>	/METHYCLOTHIAZIDE/AND/DESERPIDINE/		
>DLT> /BP/	/BOLAR/	/0.25MG;5MG/	/N88486/001/ /AUG/10,/1984/
>DLT>			
>DLT> /BP/		/0.5MG;5MG/	/N88452/001/ /AUG/10,/1984/
>DLT>			
>ADD>	@ BOLAR	0.25MG;5MG	N88486 001 AUG 10, 1984
>ADD>			
>ADD>	@	0.5MG;5MG	N88452 001 AUG 10, 1984
>ADD>			

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL		
/AB/	/PHARM BASICS/	/25MG/	/N71864/001/ /SEP/09,/1987/
/AB/		/50MG/	/N71865/001/ /SEP/09,/1987/
/AB/		/75MG/	/N71866/001/ /SEP/09,/1987/
/AB/		/100MG/	/N71867/001/ /SEP/09,/1987/
B*	PHARM BASICS	25MG	N71864 001 SEP 09, 1987
B*		50MG	N71865 001 SEP 09, 1987
B*		75MG	N71866 001 SEP 09, 1987
B*		100MG	N71867 001 SEP 09, 1987

DESMOPRESSIN ACETATE

SOLUTION; NASAL

	CONCENTRAID		
BX	FERRING	0.01%	N19776 001 DEC 26, 1990
		/0.01%/	/N19776/001/ /DEC/26,/1990/
	DDAVP		
BX	RHONE POULENC RORER	0.01%	N17922 001
		/0.01%/	/N17922/001/

DEXAMETHASONE

TABLET; ORAL

	DEXAMETHASONE		
>DLT> /BP/	/BOLAR/	/0.75MG/	/N84457/001/
>ADD> @	BOLAR	0.75MG	N84457 001
/BP/	/CORD/	/0.75MG/	/N80399/001/
@	CORD	0.75MG	N80399 001

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	/DEXACEN-4/		
/AP/	/CENTRAL PHARMS/	/EQ 4MG PHOSPHATE/ML/	/N84342/001/
@	CENTRAL PHARMS	EQ 4MG PHOSPHATE/ML	N84342 001
	DEXAMETHASONE SODIUM PHOSPHATE		
/AP/	/LEMMON/	/EQ 4MG PHOSPHATE/ML/	/N84355/001/

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001

SOLUTION/DROPS; OPHTHALMIC
DEXAIR

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N88433 001 DEC 15, 1983
/AT/	/PHARMAFAIR/	/EQ 0.1% PHOSPHATE/	/N88433/001/ /DEC/15,/1983/

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/10GM/100ML/	/N18504/001/
	@ CUTTER	10GM/100ML	N18504 001

DEXTROSE 50% IN PLASTIC CONTAINER

AP	BAXTER	50GM/100ML*	N20047 001 JUL 02, 1991

DEXTROSE 60% IN PLASTIC CONTAINER

AP	BAXTER	60GM/100ML*	N20047 002 JUL 02, 1991

DEXTROSE 70% IN PLASTIC CONTAINER

AP	BAXTER	70GM/100ML*	N20047 003 JUL 02, 1991

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

/AP/	/MCGAW/	/5GM/100ML;220MG/100ML;/ /450MG/100ML/	/N18268/002/
	MCGAW	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/5GM/100ML;200MG/100ML/	/N18399/001/
	@ CUTTER	5GM/100ML;200MG/100ML	N18399 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/5GM/100ML;300MG/100ML/	/N17799/001/
	ABBOTT	5GM/100ML;300MG/100ML	N17799 001
/AP/	/CUTTER/	/5GM/100ML;300MG/100ML/	/N18501/001/
	@ CUTTER	5GM/100ML;300MG/100ML	N18501 001

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/5GM/100ML;450MG/100ML/	/N18400/001/
	@ CUTTER	5GM/100ML;450MG/100ML	N18400 001

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
/DIATRIZOATE-60/

/AP/	/INTL/MEDICATION/	/52%;8%/	/N88166/001/ /JUN/17,/1983/
	@ INTL MEDICATION	52%;8%	N88166 001 JUN 17, 1983

DIATRIZOATE SODIUM

INJECTABLE; INJECTION
/MD-60/

/AP/	/MALLINCKRODT/	/60%/	/N87075/001/
	@ MALLINCKRODT	60%	N87075 001

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

/AP/	/LEMMON/	/5MG/ML/	/N70911/001/ /AUG/28,/1986/
/AP/		/5MG/ML/	/N70912/001/ /AUG/28,/1986/
/AP/		/5MG/ML/	/N70930/001/ /DEC/01,/1986/
AP	STERIS	5MG/ML	N70911 001 AUG 28, 1986
AP		5MG/ML	N70912 001 AUG 28, 1986
AP		5MG/ML	N70930 001 DEC 01, 1986

TABLET; ORAL
DIAZEPAM

/A/	/SUPERPHARM/	/2MG/	/N70642/001/ /DEC/11,/1985/
/A/		/5MG/	/N70643/001/ /DEC/11,/1985/
/A/		/10MG/	/N70644/001/ /DEC/11,/1985/

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN
CIBA 0.1%¤ N20037 001
MAR 28, 1991

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL
> DLT > /AB/ /BOLAR/ /10MG/ /N83179/001/
> DLT > /FEB/12,/1986/
> ADD > ə BOLAR 10MG N83179 001
> ADD > FEB 12, 1986

TABLET; ORAL
DICYCLOMINE HCL
> DLT > /AB/ /BOLAR/ /20MG/ /N84361/001/
> DLT > /FEB/06,/1986/
> ADD > ə BOLAR 20MG N84361 001
> ADD > FEB 06, 1986

> ADD > DIDANOSINE

> ADD > POWDER FOR RECONSTITUTION; ORAL
> ADD > VIDEX
> ADD > BRISTOL MYERS SQUIBB 10MG/ML¤ N20156 001
> ADD > OCT 09, 1991
> ADD > 100MG/PACKET¤ N20155 003
> ADD > OCT 09, 1991
> ADD > 167MG/PACKET¤ N20155 004
> ADD > OCT 09, 1991
> ADD > 250MG/PACKET¤ N20155 005
> ADD > OCT 09, 1991
> ADD > 375MG/PACKET¤ N20155 006
> ADD > OCT 09, 1991

> ADD > TABLET, CHEWABLE; ORAL
> ADD > VIDEX
> ADD > BRISTOL MYERS SQUIBB 25MG¤ N20154 002
> ADD > OCT 09, 1991
> ADD > 50MG¤ N20154 003
> ADD > OCT 09, 1991
> ADD > 100MG¤ N20154 004
> ADD > OCT 09, 1991
> ADD > 150MG¤ N20154 005
> ADD > OCT 09, 1991

DIETHYLSTILBESTROL

TABLET; ORAL
STILBESTROL
/BP/ /TABLICAPS/ /0.5MG/ /N83004/001/
TABLICAPS 0.5MG N83004 001
/STILBETIN/
/BP/ /SQUIBB/ /0.5MG/ /N04056/008/
/BP/ /1MG/ /N04056/009/
/BP/ /5MG/ /N04056/010/
/0.1MG/ /N04056/007/
/0.25MG/ /N04056/017/
ə SQUIBB 0.1MG N04056 007
ə 0.25MG N04056 017
ə 0.5MG N04056 008
ə 1MG N04056 009
ə 5MG N04056 010

DILTIAZEM HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > CARDIZEM
> ADD > MARION MERRELL DOW 25MG/VIAL¤ N20027 001
> ADD > OCT 24, 1991
> ADD > 50MG/VIAL¤ N20027 002
> ADD > OCT 24, 1991

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /LEMMON/ /50MG/ML/ /N83531/001/
AP STERIS 50MG/ML N83531 001

LIQUID; ORAL
DIMENHYDRINATE
ə ALRA 12.5MG/4ML N80715 001
/ə/BANMAX/ /12.5MG/4ML/ /N80715/001/

/TABLET;/ORAL/
/DIMENHYDRINATE/
/AA/ /CHELSEA/ /50MG/ /N85166/001/
ə CHELSEA 50MG N85166 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
ə ALRA 25MG N80519 004
ə 50MG N80519 003

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

/Ø/	/BANMAX/	/50MG/	/N065119/003/	

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

/AA/	/KV/	/12.5MG/5ML/	/N085621/001/	
	∂ KV	12.5MG/5ML	N85621 001	

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

/AP/	/ELKINS/SINN/	/50MG/ML/	/N083183/001/	
	∂ ELKINS SINN	50MG/ML	N83183 001	
/AP/	/LEMMON/	/10MG/ML/	/N083533/001/	
AP	STERIS	10MG/ML	N83533 001	

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

> ADD >	AB	GENEVA	25MG	N86944 002 APR 16, 1991
> ADD >	AB	LEDERLE	25MG	N88999 001 FEB 05, 1991
	AB		50MG	N89000 001 FEB 05, 1991
	AB		75MG	N89001 001 FEB 05, 1991

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

> DLT >	/AB/	/BOLAR/	/EQ 100MG BASE/	/N70240/001/ /FEB/02,/1986/
> DLT >	/AB/		/EQ 150MG BASE/	/N70241/001/ /FEB/02,/1986/
> ADD >		∂ BOLAR	EQ 100MG BASE	N70240 001 FEB 02, 1986
> ADD >		∂	EQ 150MG BASE	N70241 001 FEB 02, 1986
	B*	CHELSEA	EQ 100MG BASE	N71020 001 DEC 01, 1986
	B*		EQ 150MG BASE	N71021 001 DEC 01, 1986
	/BX/		/EQ 100MG BASE/	/N71020/001/ /DEC/01,/1986/
	/BX/		/EQ 150MG BASE/	/N71021/001/ /DEC/01,/1986/

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

/AB/	/MYLAN/	/EQ 100MG BASE/	/N70138/001/ /JUN/14,/1985/
/AB/		/EQ 150MG BASE/	/N70139/001/ /JUN/14,/1985/
	∂ MYLAN	EQ 100MG BASE	N70138 001 JUN 14, 1985
	∂	EQ 150MG BASE	N70139 001 JUN 14, 1985

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTREX
LILLY — EQ 12.5MG BASE/ML /EQ/250MG/BASE/VIAL/ — N17820 002 /N17820/002/

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

> ADD >	AP	GENSIA	40MG/ML	N72999 001 OCT 23, 1991
> ADD >	AP		80MG/ML	N73000 001 OCT 23, 1991
/AP/	/SOLOPAK/	/40MG/ML/	/N70011/001/ /AUG/29,/1985/	
	∂ SOLOPAK	40MG/ML	N70011 001 AUG 29, 1985	

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION
NUROMAX
BURROUGHS WELLCOME — EQ 1MG BASE/ML — N19946 001 MAR 07, 1991

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

>DLT >/AB/	/BARR/	/EQ 25MG BASE/	/N71502/001/ /FEB/18,/1988/	
>DLT >				
>DLT >/AB/		/EQ 50MG BASE/	/N71653/001/ /FEB/18,/1988/	
>DLT >				
>DLT >/AB/		/EQ 75MG BASE/	/N71654/001/ /FEB/18,/1988/	
>DLT >				
>DLT >/AB/		/EQ 100MG BASE/	/N71521/001/ /FEB/18,/1988/	
>DLT >				
>ADD >	∂ BARR	EQ 25MG BASE	N71502 001 FEB 18, 1988	
>ADD >				
>ADD >	∂	EQ 50MG BASE	N71653 001 FEB 18, 1988	
>ADD >				
>ADD >	∂	EQ 75MG BASE	N71654 001 FEB 18, 1988	
>ADD >				
>ADD >	∂	EQ 100MG BASE	N71521 001 FEB 18, 1988	
>ADD >				
/B*/	/CHELSEA/	/EQ/10MG/BASE¤/	/N70952/001/ /MAR/04,/1987/	
/B*/		/EQ/25MG/BASE¤/	/N70953/001/ /MAY/15,/1986/	
/B*/		/EQ/50MG/BASE¤/	/N70954/001/ /MAY/15,/1986/	
/B*/		/EQ/75MG/BASE¤/	/N71763/001/ /FEB/09,/1988/	
/B*/		/EQ/100MG/BASE¤/	/N70955/001/ /MAY/15,/1986/	
/B*/		/EQ/150MG/BASE¤/	/N71764/001/ /FEB/09,/1988/	
	∂ CHELSEA	EQ 10MG BASE¤	N70952 001 MAR 04, 1987	
	∂	EQ 25MG BASE¤	N70953 001 MAY 15, 1986	
	∂	EQ 50MG BASE¤	N70954 001 MAY 15, 1986	
	∂	EQ 75MG BASE¤	N71763 001 FEB 09, 1988	
	∂	EQ 100MG BASE¤	N70955 001 MAY 15, 1986	
	∂	EQ 150MG BASE¤	N71764 001 FEB 09, 1988	
/AB/	/PUREPAC/	/EQ 75MG BASE/	/N72386/001/ /SEP/08,/1988/	
/AB/		/EQ 150MG BASE/	/N72387/001/ /SEP/08,/1988/	
	∂ PUREPAC	EQ 75MG BASE	N72386 001 SEP 08, 1988	
	∂	EQ 150MG BASE	N72387 001 SEP 08, 1988	

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

AB	ROYCE	EQ 10MG BASE¤	N72985 001 MAR 29, 1991
AB		EQ 25MG BASE¤	N72986 001 MAR 29, 1991
AB		EQ 50MG BASE¤	N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

AP	ADRIA	2MG/ML	N50629 001 DEC 23, 1987
AP		200MG/100ML	N50629 002 MAY 03, 1988
AP		2MG/ML¤	N63165 001 JAN 30, 1991
AP		200MG/100ML¤	N63165 002 JAN 30, 1991
		/2MG/ML/	/N50629/002/ /MAY/03,/1988/

DOXORUBICIN HCL

AP	CETUS BEN VENUE	2MG/ML	N62975 001 MAR 17, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/AB/	/SUPERPHARM/	/EQ 50MG BASE/	/N62469/001/ /OCT/31,/1984/	
/AB/		/EQ 100MG BASE/	/N62469/002/ /OCT/31,/1984/	
	∂ SUPERPHARM	EQ 50MG BASE	N62469 001 OCT 31, 1984	
	∂	EQ 100MG BASE	N62469 002 OCT 31, 1984	

TABLET; ORAL

DOXYCYCLINE HYCLATE

/AB/	/CHELSEA/	/EQ 100MG BASE/	/N62392/002/ /MAR/31,/1983/	
	∂ CHELSEA	EQ 100MG BASE	N62392 002 MAR 31, 1983	

DOXYLAMINE SUCCINATE

/TABLET;/ORAL/
/DOXYLAMINE SUCCINATE/

/AA/	/COPLEY/	/25MG/	/N86906/001/	/OCT/06,/1985/

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML/	/N72020/001/	/OCT/19,/1988/
	ə ASTRA	2.5MG/ML	N72020 001	OCT 19, 1988

EDETATE DISODIUM

INJECTABLE; INJECTION
DISODIUM EDETATE

/AP/	/LEMMON/	/150MG/ML/	/N84356/001/	
AP	STERIS	150MG/ML	N84356 001	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

/ə/	/LEMMON/	/0.01MG/ML;1%/	/N85463/001/	
	ə STERIS	0.01MG/ML;1%	N85463 001	

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

>DLT>	/AB/	/BOLAR/	/1MG/	/N86433/001/	
>DLT>				/MAY/27,/1982/	
>ADD>		ə BOLAR	1MG	N86433 001	
>ADD>				MAY 27, 1982	
>ADD>	AB	MUTUAL PHARM	1MG¤	N81113 001	
>ADD>				OCT 31, 1991	

TABLET; SUBLINGUAL
/DEAFRIL-ST/

/AA/	/BRISTOL/MYERS/SQUIBB/1MG/		/N85020/002/	
	ə BRISTOL MYERS SQUIBB 1MG		N85020 002	

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
ERGOLOID MESYLATES

>DLT>	/AA/	/BOLAR/	/0.5MG/	/N84930/001/	
>DLT>	/AA/		/1MG/	/N85177/001/	
>ADD>		ə BOLAR	0.5MG	N84930 001	
>ADD>		ə	1MG	N85177 001	
	/AA/	/KV/	/0.5MG/	/N86265/001/	
	/AA/		/1MG/	/N86264/001/	
		ə KV	0.5MG	N86265 001	
		ə	1MG	N86264 001	

ERYTHROMYCIN

GEL; TOPICAL
E/GEL

	/FULTON/	/2%/	/N63107/001/	/AUG/23,/1991/
	EMGEL			
AT	GLAXO	2%¤	N63107 001	
			AUG 23, 1991	
	ERYGEL			
AT	HERBERT	2%	N50617 001	
			OCT 21, 1987	

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	CLAY PARK	2%¤	N63038 001	
			JAN 11, 1991	
/AT/	/LILLY/	/2%/	/N50532/001/	
	ə LILLY	2%	N50532 001	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

/AB/	/NASKA/	/EQ 400MG BASE/5ML/	/N62674/001/	/MAR/10,/1987/	
	ə NASKA	EQ 400MG BASE/5ML	N62674 001		
			MAR 10, 1987		

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

>DLT>	/DUPONT/	/100MG/ML/	/N19386/003/	/DEC/31,/1986/	
>DLT>					
>ADD>	ə DUPONT	100MG/ML	N19386 003		
>ADD>			DEC 31, 1986		

ESTROGENS, CONJUGATED

TABLET; ORAL

CONJUGATED ESTROGENS

/BP/	/CHELSEA/	/1.25MG/	/N85001/001/
/BP/		/2.5MG/	/N85826/001/
	/a/	/0.625MG/	/N85000/001/
	/a/CORD/	/0.3MG/	/N86070/001/
	/a/	/0.625MG/	/N83761/001/
	/a/	/1.25MG/	/N83763/001/
	/a/	/2.5MG/	/N83762/001/
	/a/DURAMED/	/0.3MG□/	/N86492/001/
	/a/	/0.625MG□/	/N83272/001/
	/a/	/1.25MG□/	/N83294/001/
	/a/	/2.5MG□/	/N83295/001/
	/a/HEATHER/	/0.625MG/	/N83356/001/
	/a/	/1.25MG/	/N83360/001/
	/a/	/2.5MG/	/N84650/001/
	/a/PRIVATE/FORM/	/0.625MG/	/N83354/003/
	/a/	/1.25MG/	/N83592/001/
	/a/	/2.5MG/	/N85908/001/
/BP/	/ZENITH/	/0.3MG/	/N88569/001/ /NOV/29,/1984/
/BP/		/0.625MG/	/N83373/001/
/BP/		/1.25MG/	/N83601/001/
/BP/		/2.5MG/	/N83602/001/

a ZENITH	0.3MG	N88569 001 NOV 29, 1984
a	0.625MG	N83373 001
a	1.25MG	N83601 001
a	2.5MG	N83602 001

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

/MILPREM-200/

/BS/	/WALLACE/	/0.45MG;200MG/	/N11045/002/

a WALLACE	0.45MG;200MG	N11045 002

/MILPREM-400/

/BS/	/WALLACE/	/0.45MG;400MG/	/N11045/001/

a WALLACE	0.45MG;400MG	N11045 001
PMB 200		
/BS/ /WYETH/AYERST/	/0.45MG;200MG/	/N10971/005/
WYETH AYERST	0.45MG;200MG	N10971 005
PMB 400		
/BS/ /WYETH/AYERST/	/0.45MG;400MG/	/N10971/003/
WYETH AYERST	0.45MG;400MG	N10971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

/AMNESTROGEN/

/BS/	/SQUIBB/	/0.625MG/	/N83266/002/
/BS/		/1.25MG/	/N83266/003/
/BS/		/2.5MG/	/N83266/004/

a SQUIBB	0.625MG	N83266 002
a	1.25MG	N83266 003
a	2.5MG	N83266 004

/ESTERIFIED/ESTROGENS/

/BS/	/PRIVATE/FORM/	/2.5MG/	/N85907/001/

a PRIVATE FORM	2.5MG	N85907 001

/EVEX/

/BS/	/SYNTEX/	/0.625MG/	/N84215/001/
/BS/		/1.25MG/	/N83376/002/

a SYNTEX	0.625MG	N84215 001
a	1.25MG	N83376 002

/FEMOGEN/

/BS/	/PRIVATE/FORM/	/0.625MG/	/N85076/001/

a PRIVATE FORM	0.625MG	N85076 001

ESTROPIPATE

TABLET; ORAL

OGEN

AB	ABBOTT	0.75MG	N83220 001
AB		1.5MG	N83220 002

ORTHO-EST

AB	JOHNSON RW	0.75MG□	N89567 001 FEB 27, 1991
AB		1.5MG□	N89582 001 JUL 17, 1991

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

/NORETHINDRONE AND ETHINYL ESTRADIOL/

/AB/	/WATSON/	/0.035MG;0.5MG AND 1MG/	/N71043/001/ /APR/01,/1988/

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB	WATSON	0.035MG;0.5MG AND 1MG	N71043 001 APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)		
WATSON	0.035MG;0.5MG AND 1MG□	N71041 001 SEP 24, 1991

TABLET; ORAL-28

/NORETHINDRONE AND ETHINYL ESTRADIOL/

/AB/	/WATSON/	/0.035MG;0.5MG AND 1MG/	/N71044/001/ /APR/01,/1988/

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB	WATSON	0.035MG;0.5MG AND 1MG	N71044 001	APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	WATSON	0.035MG;0.5MG AND 1MG¤	N71042 001	SEP 24, 1991

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

/TABLET;ORAL-28/
/NORLESTRIN/28/1/50/
/PARKE/DAVIS/ /0.05MG;1MG/ /N16723/001/

TABLET; ORAL-28

NORLESTRIN 28 1/50

	∂ PARKE DAVIS	0.05MG;1MG	N16723 001

ETODOLAC

CAPSULE; ORAL

LODINE

	WYETH AYERST	200MG¤	N18922 002 JAN 31, 1991
		300MG¤	N18922 003 JAN 31, 1991

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

	MSD	5MG¤	N19834 001 JUL 26, 1991
		10MG¤	N19834 002 JUL 26, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB	DANBURY	EQ 200MG BASE¤	N72981 001	AUG 19, 1991
AB		EQ 300MG BASE¤	N72982 001	AUG 19, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB	WARNER CHILCOTT	EQ 200MG BASE¤	N72946 001	APR 30, 1991
AB		EQ 300MG BASE¤	N72472 001	APR 30, 1991

TABLET; ORAL

FENOPROFEN CALCIUM

/AB/	/PHARM/BASICS/	/EQ 600MG BASE/	/N72362/001/	/JUN/16,/1988/
	∂ PHARM BASICS	EQ 600MG BASE	N72362 001	JUN 16, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	STERLING	EQ 0.05MG BASE/ML¤	N72786 001	SEP 24, 1991

FIBRINOGEN, I-125

INJECTABLE; INJECTION

/IBRIN/

>DLT>	/AMERSHAM/	/154/UCI/VIAL/	/N17879/001/	
>DLT>	∂ AMERSHAM	154 UCI/VIAL	N17879 001	
>ADD>				

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

	BERLEX	50MG/VIAL¤	N20038 001 APR 18, 1991

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

/FLUOCET/

/AT/	/NMC/	/0.01%/	/N88361/001/	/JAN/16,/1984/

FLUOCINOLONE ACETONIDE

AT	NMC	0.01%	N88361 001	JAN 16, 1984

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	TARO	0.05%	N19117 001 JUN 26, 1984	
AB	TICAN	0.05%	N72494 001 JAN 19, 1989	
/AB/	/VASODERM/ /TARO/	/0.05%/	/N19117/001/ /JUN/26,/1984/	
/AB/	/VASODERM E/ /TICAN/	/0.05%/	/N72494/001/ /JAN/19,/1989/	

FLUOROURACIL

INJECTABLE; INJECTION

	ADRUCIL			
> ADD > AP	ADRIA	50MG/ML*	N40023 001 OCT 18, 1991	
> ADD > AP		50MG/ML*	N81222 001 JUN 28, 1991	
AP		50MG/ML*	N81225 001 AUG 28, 1991	
	FLUOROURACIL			
/AP/	/SOLOPAK/	/50MG/ML/	/N88766/001/ /DEC/28,/1984/	
	ə SOLOPAK	50MG/ML	N88766 001 DEC 28, 1984	

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

PROZAC LILLY	EQ 20MG BASE/5ML*	N20101 001 APR 24, 1991	

FLUOXYMESTERONE

TABLET; ORAL

	FLUOXYMESTERONE			
> DLT > /BP/	/BOLAR/	/2MG/	/N88260/001/ /DEC/06,/1983/	
> DLT >				
> DLT > /BP/		/5MG/	/N88265/001/ /DEC/06,/1983/	
> DLT >				
> DLT > /BP/		/10MG/	/N88309/001/ /DEC/06,/1983/	
> DLT >				
> ADD >	ə BOLAR	2MG	N88260 001 DEC 06, 1983	
> ADD >				
> ADD >	ə	5MG	N88265 001 DEC 06, 1983	
> ADD >				
> ADD >	ə	10MG	N88309 001 DEC 06, 1983	
> ADD >				

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	FLUPHENAZINE HCL		
AA	COPLEY	5MG/ML*	N73058 001 AUG 30, 1991

TABLET; ORAL

	FLUPHENAZINE HCL			
> DLT > /AB/	/BOLAR/	/1MG/	/N88555/001/ /DEC/18,/1987/	
> DLT >				
> DLT > /AB/		/2.5MG/	/N88544/001/ /DEC/18,/1987/	
> DLT >				
> DLT > /AB/		/5MG/	/N88527/001/ /DEC/18,/1987/	
> DLT >				
> DLT > /AB/		/10MG/	/N88550/001/ /DEC/18,/1987/	
> DLT >				
> ADD >	ə BOLAR	1MG	N88555 001 DEC 18, 1987	
> ADD >				
> ADD >	ə	2.5MG	N88544 001 DEC 18, 1987	
> ADD >				
> ADD >	ə	5MG	N88527 001 DEC 18, 1987	
> ADD >				
> ADD >	ə	10MG	N88550 001 DEC 18, 1987	
> ADD >				

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	FLURAZEPAM HCL		
AB	GENEVA	15MG*	N71716 001 JUL 31, 1991
AB		30MG*	N71717 001 JUL 31, 1991

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/AB/	/PHARM/BASICS/	/15MG/	/N70562/001/ /JUL/09,/1987/
/AB/		/30MG/	/N70563/001/ /JUL/09,/1987/
B*	PHARM BASICS	15MG	N70562 001 JUL 09, 1987
B*		30MG	N70563 001 JUL 09, 1987

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCAVIR

	ASTRA	24MG/ML¤	N20068 001 SEP 27, 1991

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL

	BRISTOL MYERS SQUIBB	10MG¤	N19915 002 MAY 16, 1991
		20MG¤	N19915 003 MAY 16, 1991

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/SOLOPAK/	/10MG/ML/	/N70023/001/ /FEB/05,/1986/
	@ SOLOPAK	10MG/ML	N70023 001 FEB 05, 1986
AP	STERLING	10MG/ML¤	N72080 001 AUG 13, 1991

SOLUTION; ORAL
FUROSEMIDE

AA	PHARM BASICS	10MG/ML	N70655 001 OCT 02, 1987

MYROSEMIDE

/AA/	/PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02,/1987/

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

	FUJISAWA	25MG/ML¤	N19961 002 JAN 17, 1991

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

>DLT >/AT/	/PACO/	/EQ 3MG BASE/ML/	/N62932/001/ /NOV/07,/1988/
>DLT > >ADD > >ADD >	@ PACO	EQ 3MG BASE/ML	N62932 001 NOV 07, 1988

GENTIAN VIOLET

/TAMPON;/VAGINAL/
/GENAPAX/

	/KEY/PHARMS/	/5MG/	/N85017/001/
	@ KEY PHARMS	5MG	N85017 001

GLUTETHIMIDE

TABLET; ORAL
/DORIDEN/

/AA/	/RHONE/POULENC/RORER/	/250MG/	/N009519/002/
/AA/		/500MG/	/N009519/005/
	@ RHONE POULENC RORER	250MG	N09519 002
	@	500MG	N09519 005
	GLUTETHIMIDE		
/AA/	/CHELSEA/	/500MG/	/N85763/001/
	@ CHELSEA	500MG	N85763 001

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	GENSIA	0.2MG/ML¤	N81169 001 SEP 10, 1991

TABLET; ORAL
GLYCOPYRROLATE

>DLT >/AA/	/BOLAR/	/1MG/	/N85562/001/
>ADD >	@ BOLAR	1MG	N85562 001

GUANETHIDINE MONOSULFATE

TABLET; ORAL

>DLT >	/GUANETHIDINE MONOSULFATE/			
>DLT >/AB/	/BOLAR/	/EQ 10MG SULFATE/	/N86113/001/	/MAR/26,/1985/
>DLT >				
>DLT >/AB/		/EQ 25MG SULFATE/	/N86114/001/	/MAR/26,/1985/
>DLT >				
>ADD >	ə BOLAR	EQ 10MG SULFATE	N86113 001	MAR 26, 1985
>ADD >				
>ADD >	ə	EQ 25MG SULFATE	N86114 001	MAR 26, 1985
>ADD >				

ISMELIN

>DLT >/AB/	/CIBA/	/EQ 10MG SULFATE/	/N12329/001/	
>DLT >/AB/		/EQ 25MG SULFATE/	/N12329/002/	
>ADD >	CIBA	EQ 10MG SULFATE	N12329 001	
>ADD >		EQ 25MG SULFATE	N12329 002	

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE

/BRISTOL/MYERS/SQUIBB/0.05%/		/N19967/001/	/DEC/27,/1990/
WESTWOOD SQUIBB	0.05%	N19967 001	DEC 27, 1990

OINTMENT; TOPICAL

ULTRAVATE

/BRISTOL/MYERS/SQUIBB/0.05%/		/N19968/001/	/DEC/17,/1990/
WESTWOOD SQUIBB	0.05%	N19968 001	DEC 17, 1990

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>DLT >/AB/	/BOLAR/	/0.5MG/	/N71571/001/	/JUN/03,/1988/
>DLT >				
>DLT >/AB/		/1MG/	/N71572/001/	/JUN/03,/1988/
>DLT >				
>DLT >/AB/		/2MG/	/N71573/001/	/JUN/03,/1988/
>DLT >				
>DLT >/AB/		/5MG/	/N71574/001/	/JUN/03,/1988/
>DLT >				
>DLT >/AB/		/10MG/	/N71575/001/	/JUN/03,/1988/
>DLT >				
>DLT >/AB/		/20MG/	/N71576/001/	/JUN/03,/1988/
>DLT >				
>ADD >	ə BOLAR	0.5MG	N71571 001	JUN 03, 1988
>ADD >				
>ADD >	ə	1MG	N71572 001	JUN 03, 1988
>ADD >				
>ADD >	ə	2MG	N71573 001	JUN 03, 1988
>ADD >				
>ADD >	ə	5MG	N71574 001	JUN 03, 1988
>ADD >				
>ADD >	ə	10MG	N71575 001	JUN 03, 1988
>ADD >				
>ADD >	ə	20MG	N71576 001	JUN 03, 1988
>ADD >				
AB	DANBURY	10MG◈	N72113 001	AUG 27, 1991
AB		20MG◈	N72353 001	AUG 27, 1991

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

/AP/	/LEMMON/	/EQ 5MG BASE/ML/	/N70713/001/	/MAY/17,/1988/
/AP/		/EQ 5MG BASE/ML/	/N70714/001/	/MAY/17,/1988/
/AP/		/EQ 5MG BASE/ML/	/N70744/001/	/MAY/17,/1988/
/AP/	/SOLOPAK/	/EQ 5MG BASE/ML/	/N70802/001/	/DEC/14,/1987/
	ə SOLOPAK	EQ 5MG BASE/ML	N70802 001	DEC 14, 1987

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70714 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

/AP/	/INTL/MEDICATION/	/10 UNITS/ML/	/N86357/001/
	@ INTL MEDICATION	10 UNITS/ML	N86357 001
		/500 UNITS/ML/	/N86357/002/
	@	500 UNITS/ML	N86357 002
/AP/	/SOLOPAK/	/100 UNITS/ML/	/N87959/001/ /APR/20,/1983/
	@ SOLOPAK	100 UNITS/ML	N87959 001 APR 20, 1983

HEPARIN SODIUM

/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17029/002/
	@ LYPHOMED	5,000 UNITS/ML	N17029 002
	/HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%/		
/AP/	/ABBOTT/	/10,000 UNITS/100ML/	/N18911/006/ /JAN/30,/1985/
	@ ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985
	/HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER/		
/AP/	/MCGAW/	/5,000 UNITS/100ML/	/N19135/001/ /MAR/29,/1985/
	@ MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

/AP/	/SOLOPAK/	/20MG/ML/	/N88517/001/ /AUG/22,/1985/
/AP/		/20MG/ML/	/N88518/001/ /APR/20,/1984/
	@ SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985
	@	20MG/ML	N88518 001 APR 20, 1984

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

/AA/	/CHELSEA/	/25MG/		/N85532/002/ /MAY/24,/1982/
/AA/		/50MG/		/N85533/002/ /MAY/25,/1982/
	@ CHELSEA	25MG		N85532 002 MAY 24, 1982
	@	50MG		N85533 002 MAY 25, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

>DLT >/AB/	/BOLAR/	/25MG;25MG/		/N85457/001/ /MAR/04,/1982/
>DLT >/AB/		/50MG;50MG/		/N85446/001/ /MAR/04,/1982/
>DLT >/AB/		/100MG;50MG/		/N85440/001/ /MAR/04,/1982/
>ADD >	@ BOLAR	25MG;25MG		N85457 001 MAR 04, 1982
>ADD >	@	50MG;50MG		N85446 001 MAR 04, 1982
>ADD >	@	100MG;50MG		N85440 001 MAR 04, 1982

TABLET; ORAL
APRESOLINE-ESIDRIX

>DLT >/AB/	/CIBA/	/25MG;15MG/		/N12026/002/
>ADD >	CIBA	25MG;15MG		N12026 002
>DLT >	/HYDROCHLOROTHIAZIDE/W/HYDRALAZINE/			
>DLT > /BP/	/BOLAR/	/25MG;15MG/		/N85373/001/
>ADD >	@ BOLAR	25MG;15MG		N85373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

>DLT >	/HYDROCHLOROTHIAZIDE/W/RESERPINE/AND/HYDRALAZINE/			
>DLT > /BP/	/BOLAR/	/25MG;15MG;0.1MG/		/N83770/001/
>ADD >	@ BOLAR	25MG;15MG;0.1MG		N83770 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

		∂ ALRA	25MG	N86369 001
		∂	50MG	N83554 001
	/∂/	/BANMAX/	/25MG/	/N86369/001/
	/∂/		/50MG/	/N83554/001/
> DLT >	/AB/	/BOLAR/	/25MG/	/N83458/001/
> DLT >	/AB/		/50MG/	/N83456/001/
> DLT >	/AB/		/100MG/	/N85099/001/
> ADD >		∂ BOLAR	25MG	N83458 001
> ADD >		∂	50MG	N83456 001
> ADD >		∂	100MG	N85099 001

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

> DLT >	/AB/	/BOLAR/	/15MG;250MG/	/N70365/001/
> DLT >				/MAR/19,/1986/
> DLT >	/AB/		/25MG;250MG/	/N70366/001/
> DLT >				/APR/16,/1986/
> DLT >	/AB/		/30MG;500MG/	/N70367/001/
> DLT >				/MAR/19,/1986/
> DLT >	/AB/		/50MG;500MG/	/N70368/001/
> DLT >				/APR/16,/1986/
> ADD >		∂ BOLAR	15MG;250MG	N70365 001 MAR 19, 1986
> ADD >		∂	25MG;250MG	N70366 001 APR 16, 1986
> ADD >		∂	30MG;500MG	N70367 001 MAR 19, 1986
> ADD >		∂	50MG;500MG	N70368 001 APR 16, 1986

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

> DLT >	/BP/	/BOLAR/	/25MG;0.125MG/	/N85317/001/
	/BP/		/50MG;0.125MG/	/N83666/001/
> ADD >		∂ BOLAR	25MG;0.125MG	N85317 001
		∂	50MG;0.125MG	N83666 001

RESERPINE AND HYDROCHLOROTHIAZIDE

	/BP/	/CORD/	/50MG;0.125MG/	/N88200/001/
				/JAN/31,/1984/
		∂ CORD	50MG;0.125MG	N88200 001 JAN 31, 1984

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

/AB/	/SUPERPHARM/	/25MG;25MG/	/N89137/001/
			/AUG/26,/1985/
	∂ SUPERPHARM	25MG;25MG	N89137 001 AUG 26, 1985

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

> DLT >	/AB/	/BOLAR/	/25MG;25MG/	/N85974/001/
> ADD >		∂ BOLAR	25MG;25MG	N85974 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	SKF	25MG;50MG	N16042 002

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	GENEVA	25MG;50MG¤	N73191 001 JUL 31, 1991

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

B*	PAR	50MG;75MG	N72337 001 MAY 11, 1988
/BX/		/50MG;75MG/	/N72337/001/ /MAY/11,/1988/

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

AT	PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984

H-CORT

/AT/	/PHARMS/ASSOC/	/0.5%/	/N86823/001/
	∂ PHARMS ASSOC	0.5%	N86823 001

HC #1

/AT/	/MILES/	/0.5%/	/N80438/001/
	∂ MILES	0.5%	N80438 001

HC #4

/AT/	/MILES/	/1%/	/N80438/002/
	∂ MILES	1%	N80438 002

HYDROCORTISONE

AT	BAUSCH AND LOMB	1%	N87838 001 JUL 28, 1982
/AT/	/NASKA/	/1%/	/N89706/001/ /MAR/10,/1988/
	∂ NASKA	1%	N89706 001 MAR 10, 1988

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

/AT/	/PHARMAFAIR/	/1%/	/N87838/001/ /JUL/28,/1982/
/AT/	/WHITE/TOWNE/PAULSEN//1%/		/N80496/002/
	@ WHITE TOWNE PAULSEN	1%	N80496 002

/PENECORT/

/AT/	/PARKE/DAVIS/	/2.5%/	/N88256/001/ /JUN/06,/1984/

SYNACORT

/AT/	/SYNTEX/	/0.5%/	/N87459/001/
	@ SYNTEX	0.5%	N87459 001

LOTION; TOPICAL

HYDROCORTISONE

/AT/	/NASKA/	/1%/	/N89705/001/ /APR/25,/1988/
	@ NASKA	1%	N89705 001 APR 25, 1988

/LOTION;/TOPICAL/

/TEXACORT/

/AT/	/COOPERCARE/	/1%/	/N80425/001/

OINTMENT; TOPICAL

HYDROCORTISONE

/AT/	/NASKA/	/1%/	/N89704/001/ /MAR/10,/1988/
	@ NASKA	1%	N89704 001 MAR 10, 1988

SOLUTION; TOPICAL

PENECORT

AT	HERBERT	1%	N88214 001 JUN 06, 1984

TEXACORT

AT	GENDERM	1%	N80425 001

TABLET; ORAL

HYDROCORTISONE

/BP/	/PUREPAC/	/20MG/	/N80395/001/
	@ PUREPAC	20MG	N80395 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOCORT

/AT/	/LEMMON/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N60736/002/
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002

SUSPENSION; OTIC

OTOCORT

/AT/	/LEMMON/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62521/001/ /JUL/11,/1985/
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001 JUL 11, 1985

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

AT	CENCI	1%	N80419 001 JAN 25, 1982
/AT/	/LIFE/LABS/	/1%/	/N80419/001/ /JAN/25,/1982/

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/	/LEMMON/	/25MG/ML/	/N83759/001/
/BP/		/50MG/ML/	/N83759/002/
BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

/HYDROCORTISONE/BUTYRATE/			
/@/GIST/		/0.1%/	/N18514/001/ /MAR/31,/1982/

/LOCOID/

/OWEN/GALDERMA/		/0.1%/	/N18795/001/ /JAN/07,/1983/
LOCOID			
BROCADES PHARMA		0.1%	N18514 001 MAR 31, 1982
@ OWEN GALDERMA		0.1%	N18795 001 JAN 07, 1983

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

	/HYDROCORTISONE BUTYRATE/				
/AT/	/GIST/	/0.1%/	/N19116/001/		
			/FEB/25,/1987/		
	/LOCOID/				
/AT/	/OWEN/GALDERMA/	/0.1%/	/N19819/001/		
			/SEP/15,/1988/		
	LOCOID				
	BROCADES PHARMA	0.1%	N19116 001		
			FEB 25, 1987		
	ə OWEN GALDERMA	0.1%	N19819 001		
			SEP 15, 1988		

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE				
/AP/	/LYPHOMED/	/EQ 100MG BASE/VIAL/	/N88667/001/		
			/JUN/08,/1984/		
/AP/		/EQ 100MG BASE/VIAL/	/N88712/001/		
			/JUN/08,/1984/		
/AP/		/EQ 250MG BASE/VIAL/	/N88668/001/		
			/JUN/08,/1984/		
/AP/		/EQ 500MG BASE/VIAL/	/N88669/001/		
			/JUN/08,/1984/		
/AP/		/EQ 1GM BASE/VIAL/	/N88670/001/		
			/JUN/08,/1984/		
	ə LYPHOMED	EQ 100MG BASE/VIAL	N88667 001		
			JUN 08, 1984		
	ə	EQ 100MG BASE/VIAL	N88712 001		
			JUN 08, 1984		
	ə	EQ 250MG BASE/VIAL	N88668 001		
			JUN 08, 1984		
	ə	EQ 500MG BASE/VIAL	N88669 001		
			JUN 08, 1984		
	ə	EQ 1GM BASE/VIAL	N88670 001		
			JUN 08, 1984		

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	HYDROFLUMETHIAZIDE AND RESERPINE				
B*	PHARM BASICS	50MG;0.125MG	N88195 001		
			OCT 26, 1983		
/BP/		/50MG;0.125MG/	/N88195/001/		
			/OCT/26,/1983/		

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	/HYDROFLUMETHIAZIDE/W//RESERPINE/				
/BP/	/BOLAR/	/25MG;0.125MG/	/N88127/001/	> DLT >	
			/MAR/22,/1983/	> DLT >	
/BP/		/50MG;0.125MG/	/N88110/001/	> DLT >	
			/MAR/22,/1983/	> DLT >	
	ə BOLAR	25MG;0.125MG	N88127 001	> ADD >	
			MAR 22, 1983	> ADD >	
	ə	50MG;0.125MG	N88110 001	> ADD >	
			MAR 22, 1983	> ADD >	
	SALUTENSIN-DEMI				
/BP/	/BRISTOL/	/25MG;0.125MG/	/N12359/004/	> DLT >	
	BRISTOL	25MG;0.125MG	N12359 004	> ADD >	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROCOBALAMIN				
/AP/	/LEMMON/	/1MG/ML/	/N85528/001/		
AP	STERIS	1MG/ML	N85528 001		

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

	/DURA-LUTIN/				
/AO/	/STERIS/	/125MG/ML/	/N17439/001/		
/AO/		/250MG/ML/	/N17439/002/		
	HYDROXYPROGESTERONE CAPROATE				
AO	STERIS	125MG/ML	N17439 001		
AO		250MG/ML	N17439 002		

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL				
/AP/	/LEMMON/	/25MG/ML/	/N87274/001/		
/AP/		/50MG/ML/	/N87274/002/		
AP	STERIS	25MG/ML	N87274 001		
AP		50MG/ML	N87274 002		

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

/AB/	/BARR/	/10MG/	/N88409/001/	/NOV/15,/1983/
>DLT >/AB/		/25MG/	/N87857/001/	/APR/18,/1983/
>DLT >				
>DLT >/AB/		/50MG/	/N87860/001/	/APR/18,/1983/
>DLT >				
>DLT >/AB/		/100MG/	/N87862/001/	/APR/18,/1983/
>DLT >				
	∂ BARR	10MG	N88409 001	NOV 15, 1983
>ADD >	∂	25MG	N87857 001	APR 18, 1983
>ADD >				
>ADD >	∂	50MG	N87860 001	APR 18, 1983
>ADD >				
>ADD >	∂	100MG	N87862 001	APR 18, 1983
>ADD >				
/AB/	/PHARM/BASICS/	/10MG/	/N89121/001/	/MAR/20,/1986/
/AB/		/25MG/	/N89122/001/	/MAR/20,/1986/
/AB/		/50MG/	/N89123/001/	/MAR/20,/1986/
B*	PHARM BASICS	10MG	N89121 001	MAR 20, 1986
B*		25MG	N89122 001	MAR 20, 1986
B*		50MG	N89123 001	MAR 20, 1986

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>DLT >/AB/	/BOLAR/	/EQ 25MG HCL/	/N86698/001/	
>DLT >/AB/		/EQ 50MG HCL/	/N86695/001/	
>DLT >/AB/		/EQ 100MG HCL/	/N86697/001/	
>ADD >	∂ BOLAR	EQ 25MG HCL	N86698 001	
>ADD >	∂	EQ 50MG HCL	N86695 001	
>ADD >	∂	EQ 100MG HCL	N86697 001	
AB	DANBURY	EQ 25MG HCL*	N81165 001	JUL 31, 1991
AB	GENEVA	EQ 25MG HCL*	N81127 001	JUN 28, 1991
AB		EQ 50MG HCL*	N81128 001	JUN 28, 1991
AB		EQ 100MG HCL*	N81129 001	JUN 28, 1991

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

/AB/	/SUPERPHARM/	/EQ 25MG HCL/	/N89031/001/	/JAN/02,/1987/
/AB/		/EQ 50MG HCL/	/N89032/001/	/JAN/02,/1987/
/AB/		/EQ 100MG HCL/	/N89033/001/	/JAN/02,/1987/
	∂ SUPERPHARM	EQ 25MG HCL	N89031 001	JAN 02, 1987
	∂	EQ 50MG HCL	N89032 001	JAN 02, 1987
	∂	EQ 100MG HCL	N89033 001	JAN 02, 1987
/AB/	/VANGARD/	/EQ 25MG HCL/	/N88392/001/	/SEP/19,/1983/
	∂ VANGARD	EQ 25MG HCL	N88392 001	SEP 19, 1983

IBUPROFEN

SUSPENSION; ORAL

RUFEN

BX	BOOTS	100MG/5ML	N19784 001	DEC 18, 1989

TABLET; ORAL

IBUPROFEN

/B*/	/CHELSEA/	/400MG#/	/N70038/001/	/SEP/06,/1985/
/B*/		/600MG#/	/N70041/001/	/SEP/06,/1985/
/B*/		/800MG#/	/N71911/001/	/OCT/13,/1987/
	∂ CHELSEA	400MG	N70038 001	SEP 06, 1985
	∂	600MG	N70041 001	SEP 06, 1985
	∂	800MG	N71911 001	OCT 13, 1987
/BX/	/SUPERPHARM/	/400MG/	/N70708/001/	/APR/25,/1986/

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

		IMIPRAMINE HCL		
> DLT >	/AB/	/BOLAR/	/10MG/	/N85220/001/
> DLT >	/AB/		/25MG/	/N84252/002/
> DLT >	/AB/		/50MG/	/N85221/001/
> ADD >		ə BOLAR	10MG	N85220 001
> ADD >		ə	25MG	N84252 002
> ADD >		ə	50MG	N85221 001
		PRAMINE		
		ə ALRA	10MG	N83827 001
		ə	25MG	N83827 002
		ə	50MG	N83827 003
		/ə/BANMAX/	/10MG/	/N83827/001/
		/ə/	/25MG/	/N83827/002/
		/ə/	/50MG/	/N83827/003/

INDOMETHACIN

CAPSULE; ORAL

		INDOMETHACIN		
> DLT >	/AB/	/BOLAR/	/25MG/	/N70784/001/
> DLT >				/AUG/20,/1986/
> DLT >	/AB/		/50MG/	/N70785/001/
> DLT >				/AUG/20,/1986/
> ADD >		ə BOLAR	25MG	N70784 001 AUG 20, 1986
> ADD >				
> ADD >		ə	50MG	N70785 001 AUG 20, 1986
> ADD >				
	AB	DANBURY	25MG¤	N72996 001 JUL 31, 1991
	AB		50MG¤	N72997 001 JUL 31, 1991
	/AB/	/ROXANE/	/25MG/	/N70353/001/
				/JUN/18,/1985/
	/AB/		/50MG/	/N70354/001/
				/JUN/18,/1985/
		ə ROXANE	25MG	N70353 001 JUN 18, 1985
		ə	50MG	N70354 001 JUN 18, 1985
> DLT >	/AB/	/SUPERPHARM/	/25MG/	/N70487/001/
> DLT >				/OCT/10,/1986/
	/AB/		/50MG/	/N70488/001/
				/OCT/10,/1986/
> ADD >		ə SUPERPHARM	25MG	N70487 001 OCT 10, 1986
> ADD >				
		ə	50MG	N70488 001 OCT 10, 1986

IOPAMIDOL

INJECTABLE; INJECTION

	ISOVUE-M 200		
	SQUIBB	41%	N18735 001 DEC 31, 1985
	ISOVUE-200		
	/SQUIBB/	/41%/	/N18735/001/ /DEC/31,/1985/
	SQUIBB	41%¤	N18735 006 JUL 07, 1987

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

		ISOETHARINE HCL		
/AN/		/ARMOUR/	/0.125%/	/N89615/001/ /JUN/13,/1991/
/AN/			/0.167%/	/N89616/001/ /JUN/13,/1991/
/AN/			/0.2%/	/N89617/001/ /JUN/13,/1991/
/AN/			/0.25%/	/N89618/001/ /JUN/13,/1991/
			/0.062%/	/N89614/001/ /JUN/13,/1991/
AN		ASTRA	0.125%¤	N89615 001 JUN 13, 1991
AN			0.167%¤	N89616 001 JUN 13, 1991
AN			0.2%¤	N89617 001 JUN 13, 1991
AN			0.25%¤	N89618 001 JUN 13, 1991
			0.062%¤	N89614 001 JUN 13, 1991

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

		BRONKOMETER		
/BN/	/STERLING/		/0.34MG/BASE/INH/	/N12339/001/
BN	STERLING		0.34MG/INH	N12339 007

ISONIAZID

SYRUP; ORAL

		/RIMIFON/		
/AA/		/ROCHE/	/50MG/5ML/	/N08420/001/
	ə ROCHE		50MG/5ML	N08420 001

ISONIAZID

TABLET; ORAL

ISONIAZID

>DLT >/AA/	/BOLAR/	/100MG/	/N80401/001/	
>DLT >/AA/		/300MG/	/N83178/001/	
>ADD >	@ BOLAR	100MG	N80401 001	
>ADD >	@	300MG	N83178 001	
AA	ZENITH	300MG	N83610 001	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

>DLT >/AP/	/INTL/MEDICATION/	/EQ 500MG BASE/2ML/	/N62466/001/ /SEP/30,/1983/
>DLT >			
>DLT >/AP/		/EQ 1GM BASE/3ML/	/N62466/002/ /SEP/30,/1983/
>DLT >			
>ADD >	@ INTL MEDICATION	EQ 500MG BASE/2ML	N62466 001 SEP 30, 1983
>ADD >			
>ADD >	@	EQ 1GM BASE/3ML	N62466 002 SEP 30, 1983
>ADD >			

KETOCONAZOLE

/SUSPENSION;/ORAL/

/NIZORAL/

/JANSSEN/	/100MG/5ML/	/N70767/001/ /NOV/07,/1986/	
@ JANSSEN	100MG/5ML	N70767 001 NOV 07, 1986	

LEVONORGESTREL

IMPLANT; IMPLANTATION

/LEVONORGESTREL/SYSTEM/

/WYETH/AYERST/	/36MG/IMPLANT/	/N20088/001/ /DEC/10,/1990/	
NORPLANT SYSTEM			
WYETH AYERST	36MG/IMPLANT	N20088 001 DEC 10, 1990	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

/AP/	/CUTTER/	/1%/	/N80414/001/
/AP/		/2%/	/N80414/002/
@ CUTTER		1%	N80414 001
@		2%	N80414 002
/AP/	/ELKINS/SINN/	/0.5%/	/N85131/001/
/AP/		/4%/	/N84626/001/
@ ELKINS SINN		0.5%	N85131 001
@		4%	N84626 001
/@/LEMMON/		/1%/	/N83627/001/
/@/		/2%/	/N83627/002/
@ STERIS		1%	N83627 001
@		2%	N83627 002

SOLUTION; TOPICAL

LIDOCAINE HCL

/AT/	/PACO/	/4%/	/N89688/001/ /JUN/30,/1989/
@ PACO		4%	N89688 001 JUN 30, 1989

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN HCL

AP	STERIS	EQ 300MG BASE/ML	N63180 001 APR 16, 1991

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

>DLT >/AB/	/SKF/	/EQ 0.025MG BASE/	/N10379/002/
>ADD >	SKF	EQ 0.025MG BASE	N10379 002
>DLT >	/LIOTHYRONINE SODIUM/		
>DLT >/AB/	/BOLAR/	/EQ 0.025MG BASE/	/N85755/001/ /JAN/25,/1982/
>DLT >			
>ADD >	@ BOLAR	EQ 0.025MG BASE	N85755 001 JAN 25, 1982
>ADD >			

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

>DLT >/AB/	/BOLAR/	/300MG/	/N70407/001/ /MAR/19,/1987/	
>DLT > >ADD > >ADD >	@ BOLAR	300MG	N70407 001 MAR 19, 1987	
/AB/	/PHARM/BASICS/	/300MG/	/N72542/001/ /FEB/01,/1989/	
B*	PHARM BASICS	300MG	N72542 001 FEB 01, 1989	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

AB	JANSSEN	2MG	N17690 001	
AB		2MG	N17694 001	

LOPERAMIDE HCL

AB	MYLAN	2MG¤	N72741 001 SEP 18, 1991	
AB	NOVOPHARM	2MG¤	N73122 001 AUG 30, 1991	

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM INTENSOL

ROXANE	2MG/ML¤	N72755 001 JUN 28, 1991	

TABLET; ORAL

LORAZEPAM

/BX/	/AM THERAP/	/0.5MG/	/N70727/001/ /MAR/07,/1986/	
/BX/		/1MG/	/N70728/001/ /MAR/07,/1986/	
/BX/		/2MG/	/N70729/001/ /MAR/07,/1986/	
@ AM THERAP		0.5MG	N70727 001 MAR 07, 1986	
@		1MG	N70728 001 MAR 07, 1986	
@		2MG	N70729 001 MAR 07, 1986	

LORAZEPAM

TABLET; ORAL

LORAZEPAM

AB	MUTUAL PHARM	0.5MG¤	N72553 001 MAR 29, 1991	
AB		1MG¤	N72554 001 MAR 29, 1991	
AB		2MG¤	N72555 001 MAR 29, 1991	
/AB/	/PHARM/BASICS/	/1MG/	/N70539/001/ /DEC/22,/1986/	
/AB/		/2MG/	/N70540/001/ /DEC/22,/1986/	
B*	PHARM BASICS	1MG	N70539 001 DEC 22, 1986	
B*		2MG	N70540 001 DEC 22, 1986	
>ADD > AB	ROYCE	0.5MG¤	N72926 001 OCT 31, 1991	
>ADD > >ADD > AB		1MG¤	N72927 001 OCT 31, 1991	
>ADD > >ADD > AB		2MG¤	N72928 001 OCT 31, 1991	
>ADD >				

LOVASTATIN

TABLET; ORAL

MEVACOR

MSD	10MG¤	N19643 002 MAR 28, 1991	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

/AP/	/CUTTER/	/10GM/100ML/	/N16472/002/	
@ CUTTER		10GM/100ML	N16472 002	

MANNITOL 15%

/AP/	/CUTTER/	/15GM/100ML/	/N16472/005/	
@ CUTTER		15GM/100ML	N16472 005	

MANNITOL 20%

/AP/	/CUTTER/	/20GM/100ML/	/N16472/004/	
@ CUTTER		20GM/100ML	N16472 004	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL
MAPROTILINE HCL

>DLT >/AB/	/BOLAR/	/25MG/	/N71943/001/ /DEC/30,/1987/	
>DLT >				
>DLT >/AB/		/50MG/	/N71944/001/ /DEC/30,/1987/	
>DLT >				
>DLT >/AB/		/75MG/	/N71945/001/ /DEC/30,/1987/	
>DLT >				
>ADD >	@ BOLAR	25MG	N71943 001 DEC 30, 1987	
>ADD >				
>ADD >	@	50MG	N71944 001 DEC 30, 1987	
>ADD >				
>ADD >	@	75MG	N71945 001 DEC 30, 1987	
>ADD >				

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

/AB/	/PHARM/BASICS/	/EQ 50MG BASE/	/N71007/001/ /MAR/25,/1988/
/AB/		/EQ 100MG BASE/	/N71008/001/ /MAR/25,/1988/
B*	PHARM BASICS	EQ 50MG BASE	N71007 001 MAR 25, 1988
B*		EQ 100MG BASE	N71008 001 MAR 25, 1988

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

B*	PHARM BASICS	20MG	N70646 001 OCT 02, 1987
B*		40MG	N70647 001 OCT 02, 1987
/BX/		/20MG/	/N70646/001/ /OCT/02,/1987/
/BX/		/40MG/	/N70647/001/ /OCT/02,/1987/

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

/AP/	/ELKINS/SINN/	/25MG/ML/	/N88279/001/ /JUN/15,/1984/
/AP/		/50MG/ML/	/N88280/001/ /JUN/15,/1984/
/AP/		/75MG/ML/	/N88281/001/ /JUN/15,/1984/
/AP/		/100MG/ML/	/N88282/001/ /JUN/15,/1984/
	@ ELKINS SINN	25MG/ML	N88279 001 JUN 15, 1984
	@	50MG/ML	N88280 001 JUN 15, 1984
	@	75MG/ML	N88281 001 JUN 15, 1984
	@	100MG/ML	N88282 001 JUN 15, 1984

MEPROBAMATE

TABLET; ORAL
BAMATE

@ ALRA	200MG	N80380 001
@	400MG	N80380 002
/@/BANMAX/	/200MG/	/N80380/001/
/@/	/400MG/	/N80380/002/

MESTRANOL; NORETHYNODREL

/TABLET;ORAL-21/
/ENOVID-E/21/
/SEARLE/ /0.1MG;2.5MG/ /N10976/001/
@ SEARLE 0.1MG;2.5MG N10976 007

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

AA	GENEVA	10MG/5ML*	N73034 001 AUG 30, 1991

METAPROTERENOL SULFATE

TABLET; ORAL

METAPROTERENOL SULFATE

/AB/	/AM THERAP/	/10MG/	/N72054/001/	/JUN/23,/1988/
/AB/		/20MG/	/N72055/001/	/JUN/23,/1988/
	∂ AM THERAP	10MG	N72054 001	JUN 23, 1988
	∂	20MG	N72055 001	JUN 23, 1988
AB	DANBURY	10MG¤	N73013 001	JAN 31, 1991
AB		20MG¤	N72795 001	JAN 31, 1991
/AB/	/PHARM/BASICS/	/10MG/	/N71013/001/	/JAN/25,/1988/
/AB/		/20MG/	/N71014/001/	/JAN/25,/1988/
B*	PHARM BASICS	10MG	N71013 001	JAN 25, 1988
B*		20MG	N71014 001	JAN 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

/AP/	/BRISTOL/	/EQ 10MG BASE/ML/	/N80431/001/
AP	LYPHOMED	EQ 10MG BASE/ML	N80431 001

METHADONE HYDROCHLORIDE

/TABLET;/EFFERVESCENT;/ORAL/

/METADONE/

	/VITARINE/	/2.5MG/	/N17108/001/
		/5MG/	/N17108/002/
		/10MG/	/N17108/003/
		/40MG/	/N17108/004/
	∂ VITARINE	2.5MG	N17108 001
	∂	5MG	N17108 002
	∂	10MG	N17108 003
	∂	40MG	N17108 004

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

>ADD> AA	SCHIAPPARELLI SEARLE	50MG	N07390 001

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

>DLT>/AA/	/SEARLE/	/50MG/	/N07396/001/

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>DLT>/AA/	/BOLAR/	/500MG/	/N83605/001/
>DLT>/AA/		/750MG/	/N83605/002/
>ADD>	∂ BOLAR	500MG	N83605 001
>ADD>	∂	750MG	N83605 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX PFS

AP	ADRIA	EQ 25MG BASE/ML¤	N81242 001 AUG 23, 1991

METHOTREXATE

/AP/	/LEDERLE/	/EQ 2.5MG BASE/ML/	/N11719/004/
	LEDERLE	EQ 2.5MG BASE/ML	N11719 004

METHOTREXATE SODIUM

/AP/	/LYPHOMED/	/EQ 2.5MG BASE/ML/	/N89323/001/ /JUN/13,/1986/
/AP/		/EQ 25MG BASE/ML/	/N89322/001/ /JUN/13,/1986/
	∂ LYPHOMED	EQ 2.5MG BASE/ML	N89323 001 JUN 13, 1986
	∂	EQ 25MG BASE/ML	N89322 001 JUN 13, 1986

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

>DLT>/AB/	/BOLAR/	/2.5MG/	/N85487/001/ /MAR/11,/1982/
>DLT>			
>DLT>/AB/		/5MG/	/N85476/001/ /MAR/11,/1982/
>DLT>			
>ADD>	∂ BOLAR	2.5MG	N85487 001 MAR 11, 1982
>ADD>			
>ADD>	∂	5MG	N85476 001 MAR 11, 1982
>ADD>			
/AB/	/PHARM/BASICS/	/5MG/	/N88745/001/ /MAR/21,/1985/
B*	PHARM BASICS	5MG	N88745 001 MAR 21, 1985

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>DLT >/AB/	/BOLAR/	/125MG/	/N70245/001/	/FEB/25,/1986/
>DLT >				
>DLT >/AB/		/250MG/	/N70246/001/	/FEB/25,/1986/
>DLT >				
>DLT >/AB/		/500MG/	/N70247/001/	/FEB/25,/1986/
>DLT >				
>ADD >	ə BOLAR	125MG	N70245 001	FEB 25, 1986
>ADD >				
>ADD >	ə	250MG	N70246 001	FEB 25, 1986
>ADD >				
>ADD >	ə	500MG	N70247 001	FEB 25, 1986
>ADD >				
/AB/	/ROXANE/	/125MG/	/N70192/001/	/APR/25,/1986/
/AB/		/250MG/	/N70193/001/	/APR/25,/1986/
/AB/		/500MG/	/N70194/001/	/APR/25,/1986/
	ə ROXANE	125MG	N70192 001	APR 25, 1986
	ə	250MG	N70193 001	APR 25, 1986
	ə	500MG	N70194 001	APR 25, 1986

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

/ə/	/LEMMON/	/20MG/ML/	/N.../248/001/
/ə/		/40MG/ML/	/N85374/001/
/ə/		/80MG/ML/	/N86507/001/
ə	STERIS	20MG/ML	N87248 001
ə		40MG/ML	N85374 001
ə		80MG/ML	N86507 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	ABBOTT	EQ 40MG BASE/VIAL*	N89573 001 FEB 22, 1991
AP		EQ 125MG BASE/VIAL*	N89574 001 FEB 22, 1991
AP		EQ 500MG BASE/VIAL*	N89575 001 FEB 22, 1991
AP		EQ 1GM BASE/VIAL*	N89576 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N88676/001/ /JUN/08,/1984/
/AP/		/EQ 125MG BASE/VIAL/	/N88677/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N88678/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N89186/001/ /MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N88679/001/ /JUN/08,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N89188/001/ /MAR/28,/1986/
	ə LYPHOMED	EQ 40MG BASE/VIAL	N88676 001 JUN 08, 1984
	ə	EQ 125MG BASE/VIAL	N88677 001 JUN 08, 1984
	ə	EQ 500MG BASE/VIAL	N88678 001 JUN 08, 1984
	ə	EQ 500MG BASE/VIAL	N89186 001 MAR 28, 1986
	ə	EQ 1GM BASE/VIAL	N88679 001 JUN 08, 1984
	ə	EQ 1GM BASE/VIAL	N89188 001 MAR 28, 1986

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

/METANDREN/

/AB/	/CIBA/	/5MG/	/N03240/004/
/AB/		/10MG/	/N03240/005/
ə	CIBA	5MG	N03240 004
ə		10MG	N03240 005

METHYLTESTOSTERONE

/BP/	/PHARM/BASICS/	/10MG/	/N80271/001/
ə	PHARM BASICS	10MG	N80271 001

METHYLTESTOSTERONE

TABLET; ORAL

	/METANDREN/	/10MG/	/N03240/001/
/AB/	/CIBA/	/25MG/	/N03240/003/
	@ CIBA	10MG	N03240 001
	@	25MG	N03240 003

METHYPRYLON

TABLET; ORAL

	NOLUDAR		
	/ROCHE/	/50MG/	/N09660/002/
	@ ROCHE	50MG	N09660 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL		
AP	ABBOTT	EQ 10MG BASE/2ML¤	N73117 001 JAN 17, 1991
AP		EQ 10MG BASE/2ML¤	N73118 001 JAN 17, 1991
/AP/	/SOLOPAK/	/EQ 10MG BASE/2ML/	/N70622/001/ /MAR/02,/1987/
	@ SOLOPAK	EQ 10MG BASE/2ML	N70622 001 MAR 02, 1987

SYRUP; ORAL

	METOCLOPRAMIDE HCL		
>DLT >/AA/	/PACO/	/EQ 5MG BASE/5ML/	/N71665/001/ /DEC/05,/1988/
>DLT > >ADD > >ADD >	@ PACO	EQ 5MG BASE/5ML	N71665 001 DEC 05, 1988
AA	PHARMS ASSOC	EQ 5MG BASE/5ML¤	N72744 001 MAY 28, 1991

TABLET; ORAL

	METOCLOPRAMIDE HCL		
>DLT >/AB/	/BARR/	/EQ 10MG BASE/	/N70660/001/ /FEB/10,/1987/
>DLT > >ADD >	@ BARR	EQ 10MG BASE	N70660 001 FEB 10, 1987
>ADD > >DLT >/AB/	/BOLAR/	/EQ 10MG BASE/	/N70363/001/ /MAR/02,/1987/
>DLT > >ADD > >ADD >	@ BOLAR	EQ 10MG BASE	N70363 001 MAR 02, 1987
AB	LEDERLE	EQ 10MG BASE¤	N72639 001 MAY 09, 1991

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

	METOCLOPRAMIDE HCL		
/AB/	/MARTEC/	/EQ 10MG BASE/	/N70598/001/ /FEB/02,/1987/
/AB/	/PHARM/BASICS/	/EQ 10MG BASE/	/N70339/001/ /JUL/29,/1985/
B*	PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985
AB	SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987

METRONIDAZOLE

INJECTABLE; INJECTION

	METRONIDAZOLE		
/AP/	/INTL/MEDICATION/	/500MG/100ML/	/N70004/001/ /MAY/08,/1985/
	@ INTL MEDICATION	500MG/100ML	N70004 001 MAY 08, 1985
AP	STERIS	500MG/100ML	N70042 001 DEC 20, 1984
	METRYL IV		
/AP/	/STERIS/	/500MG/100ML/	/N70042/001/ /DEC/20,/1984/

TABLET; ORAL

	METRONIDAZOLE		
/AB/	/SUPERPHARM/	/250MG/	/N70008/001/ /DEC/11,/1984/
/AB/		/500MG/	/N70009/001/ /DEC/11,/1984/
	@ SUPERPHARM	250MG	N70008 001 DEC 11, 1984
	@	500MG	N70009 001 DEC 11, 1984

MICONAZOLE NITRATE

	/CREAM;/VAGINAL/ /MONISTAT 7/		
/AT/	/JOHNSON/RW/	/2%/	/N17456/001/
	/SUPPOSITORY;/VAGINAL/ /MONISTAT 7/		
/AT/	/JOHNSON/RW/	/100MG/	/N18526/001/ /MAR/15,/1982/

MILRINONE LACTATE

/INJECTABLE;/INJECTION/
/MILRINONE/LACTATE/
/STERLING/ /EQ/1MG/BASE/ML/ /N19436/001/ /DEC/31,/1987/

@ STERLING EQ 1MG BASE/ML N19436 001 DEC 31, 1987

MINOXIDIL

TABLET; ORAL
MINOXIDIL
/AB/ /PHARM/BASICS/ /2.5MG/ /N71537/001/ /DEC/16,/1988/

B* PHARM BASICS 2.5MG N71537 001 DEC 16, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION
INFUMORPH
ELKINS SINN 10MG/ML¤ N18565 003 JUL 19, 1991
25MG/ML¤ N18565 004 JUL 19, 1991

MORPHINE SULFATE
AP STERIS 0.5MG/ML¤ N73373 001 SEP 30, 1991
AP 0.5MG/ML¤ N73375 001 SEP 30, 1991
AP 1MG/ML¤ N73374 001 SEP 30, 1991
AP 1MG/ML¤ N73376 001 SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN
BC PURDUE FREDERICK 30MG N19516 001 MAY 29, 1987
BC 60MG N19516 002 APR 08, 1988
BC 100MG N19516 004 JAN 16, 1990

ORAMORPH SR
BC ROXANE LABS 30MG¤ N19977 001 AUG 15, 1991
BC 60MG¤ N19977 002 AUG 15, 1991
BC 100MG¤ N19977 003 AUG 15, 1991

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE
/AP/ /ELKINS/SINN/ /0.4MG/ML/ /N70496/001/ /OCT/22,/1985/

@ ELKINS SINN 0.4MG/ML N70496 001 OCT 22, 1985

NALOXONE HCL
>DLT >/AP/ /LYPHOMED/ /1MG/ML/ /N71604/001/ /DEC/16,/1988/
>DLT >
>ADD > @ LYPHOMED 1MG/ML N71604 001 DEC 16, 1988
>ADD >

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE
/AO/ /LEMMON/ /50MG/ML/ /N87598/001/ /OCT/06,/1983/
/AO/ /50MG/ML/ /N88554/001/ /FEB/10,/1986/
/AO/ /100MG/ML/ /N87599/001/ /OCT/06,/1983/

AO STERIS 50MG/ML N87598 001 OCT 06, 1983
AO 50MG/ML N88554 001 FEB 10, 1986
AO 100MG/ML N87599 001 OCT 06, 1983

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE
>DLT >/AA/ /ROXANE/ /EQ 350MG BASE/ /N62173/001/
>ADD > @ ROXANE EQ 350MG BASE N62173 001

NIACIN

TABLET; ORAL
NIACIN
/AA/ /WEST/WARD/ /500MG/ /N83718/001/
@ WEST WARD 500MG N83718 001

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	CHASE	20MG	N73421 001	JUN 19, 1991
>ADD > AB	SCHERER	10MG	N73250 001	OCT 08, 1991
>ADD >				

NITROFURAZONE

CREAM; TOPICAL

FURACIN

/NORWICH/EATON/	/0.2%/	/N83789/001/	
ROBERTS	0.2%	N83789 001	

POWDER; TOPICAL

FURACIN

/NORWICH/EATON/	/0.2%/	/N83791/001/	
ROBERTS	0.2%	N83791 001	

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

/AP/	/LYPHOMED/	/5MG/ML/	/N71203/001/	/MAY/08,/1987/
	ə LYPHOMED	5MG/ML	N71203 001	MAY 08, 1987
/AP/	/SOLOPAK/	/5MG/ML/	/N70634/001/	/JUN/19,/1986/
	ə SOLOPAK	5MG/ML	N70634 001	JUN 19, 1986
/AP/	/KREMERS/URBAN/	/0.8MG/ML/	/N18774/001/	/JAN/19,/1983/
	ə RORER	0.8MG/ML	N18774 001	JAN 19, 1983

NITROSTAT

/AP/	/PARKE/DAVIS/	/0.8MG/ML/	/N18588/001/	
	PARKE DAVIS	0.8MG/ML	N18588 001	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MSD	0.3%	N19757 001	JUN 17, 1991

NYSTATIN

CREAM; TOPICAL

/AT/	/MILES/	/100,000 UNITS/GM/	/N61810/001/	
	ə MILES	100,000 UNITS/GM	N61810 001	

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ZOFRAN

GLAXO	EQ 2MG BASE/ML	N20007 001	JAN 04, 1991

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

>DLT >/AB/	/3M/	/100MG/	/N12157/001/	
>ADD >	3M	100MG	N12157 001	
>DLT >	/ORPHENADRINE CITRATE/			
>DLT >/AB/	/BOLAR/	/100MG/	/N84303/001/	
>ADD >	ə BOLAR	100MG	N84303 001	

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

/AP/	/ELKINS/SINN/	/EQ 250MG BASE/VIAL/	/N62711/001/ /FEB/03,/1989/		
/AP/		/EQ 500MG BASE/VIAL/	/N62711/002/ /FEB/03,/1989/		
/AP/		/EQ 1GM BASE/VIAL/	/N62711/003/ /FEB/03,/1989/		
/AP/		/EQ 2GM BASE/VIAL/	/N62711/004/ /FEB/03,/1989/		
/AP/		/EQ 4GM BASE/VIAL/	/N62711/005/ /FEB/03,/1989/		
/AP/		/EQ 10GM BASE/VIAL/	/N62711/006/ /FEB/03,/1989/		
	ə ELKINS SINN	EQ 250MG BASE/VIAL	N62711 001 FEB 03, 1989		
	ə	EQ 500MG BASE/VIAL	N62711 002 FEB 03, 1989		
	ə	EQ 1GM BASE/VIAL	N62711 003 FEB 03, 1989		
	ə	EQ 2GM BASE/VIAL	N62711 004 FEB 03, 1989		
	ə	EQ 4GM BASE/VIAL	N62711 005 FEB 03, 1989		
	ə	EQ 10GM BASE/VIAL	N62711 006 FEB 03, 1989		

OXANDROLONE

/TABLET;ORAL/
/ANAVAR/
/ə/SEARLE/ /2.5MG/ /N13718/001/

TABLET; ORAL
OXANDRIN
GYNEX 2.5MG N13718 001

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

B*	CHELSEA	10MG		N71661 001 MAR 02, 1988
B*		15MG		N71662 001 MAR 02, 1988
B*		30MG		N71663 001 MAR 02, 1988
/BX/		/10MG/		/N71661/001/ /MAR/02,/1988/
/BX/		/15MG/		/N71662/001/ /MAR/02,/1988/
/BX/		/30MG/		/N71663/001/ /MAR/02,/1988/

OXTRIPHYLLINE

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL

>DLT >/AB/	/PARKE/DAVIS/	/100MG/		/N09268/003/
>DLT >/AB/		/200MG/		/N09268/007/
>ADD >	PARKE DAVIS	200MG		N09268 007
>ADD >		100MG		N09268 003

>DLT > /OXTRIPHYLLINE/

>DLT >/AB/	/BOLAR/	/100MG/		/N87866/001/ /AUG/25,/1983/
>DLT >				
>DLT >/AB/		/200MG/		/N87835/001/ /AUG/25,/1983/
>DLT >				
>ADD >	ə BOLAR	100MG		N87866 001 AUG 25, 1983
>ADD >				
>ADD >	ə	200MG		N87835 001 AUG 25, 1983
>ADD >				

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE

>DLT >/AB/	/BOLAR/	/5MG/		/N72485/001/ /APR/19,/1989/
>DLT >				
>ADD >	ə BOLAR	5MG		N72485 001 APR 19, 1989
>ADD >				

>ADD > PAMIDRONATE DISODIUM

>ADD > INJECTABLE; INJECTION
>ADD > AREDIA
>ADD > CIBA GEIGY 30MG/VIAL‡ N20036 001 OCT 31, 1991
>ADD >

> ADD > PAMIDRONATE DISODIUM

> ADD > INJECTABLE; INJECTION
> ADD > AREDIA
> ADD > CIBA GEIGY 30MG/VIAL¤ N20036 001
> ADD > OCT 31, 1991

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL
/AA/ /CHELSEA/ /100MG/ /N85791/001/
@ CHELSEA 100MG N85791 001
> DLT >/AA/ /WYETH/AYERST/ /100MG/ /N83239/001/
> ADD > @ WYETH AYERST 100MG N83239 001

> ADD > PENTOSTATIN

> ADD > INJECTABLE; INJECTION
> ADD > NIPENT
> ADD > PARKE DAVIS 10MG/VIAL¤ N20122 001
> ADD > OCT 11, 1991

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE
B* CHELSEA 8MG N89700 001
DEC 23, 1987
/BX/ /8MG/ /N89700/001/
/DEC/23,/1987/

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE
BC VITARINE 105MG N18074 001
/@/ /105MG/ /N18074/001/
/SPRX-105/
/BC/ /SOLVAY/ /105MG/ /N88024/001/
/DEC/22,/1982/
@ SOLVAY 105MG N88024 001
DEC 22, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
/AA/ /CORD/ /35MG/ /N86365/001/
@ CORD 35MG N86365 001
> ADD > AA MIKART 35MG¤ N89452 001
> ADD > OCT 30, 1991

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
/AB/ /SOLOPAK/ /50MG/ML/ /N80521/001/
/DEC/18,/1984/
@ SOLOPAK 50MG/ML N88521 001
DEC 18, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
LEO 12.5MG N19456 001
DEC 28, 1989
25MG N19456 002
DEC 28, 1989
/LILLY/ /12.5MG/ /N19456/001/
/DEC/28,/1989/
/25MG/ /N19456/002/
/DEC/28,/1989/

PIPERAZINE CITRATE

SYRUP; ORAL
PIPERAZINE CITRATE
/AA/ /BARRE/ /EQ 500MG BASE/5ML/ /N80774/001/
@ BARRE EQ 500MG BASE/5ML N80774 001

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY
BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT¤ N19797 001
APR 22, 1991

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
GLYCOPREP
AA GOLDLINE 236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N72319 001
DEC 23, 1988
/AA/ /SUPERPHARM/ /236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT/ /N72319/001/
/DEC/23,/1988/

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	/CUTTER/	/1MEQ/ML/	/N80195/002/	
/AP/		/2MEQ/ML/	/N80195/001/	
/AP/		/3MEQ/ML/	/N80195/003/	
	@ CUTTER	1MEQ/ML	N80195 002	
	@	2MEQ/ML	N80195 001	
	@	3MEQ/ML	N80195 003	
/AP/	/ELKINS/SINN/	/2MEQ/ML/	/N80203/001/	
	@ ELKINS SINN	2MEQ/ML	N80203 001	
/AP/	/LEMMON/	/2MEQ/ML/	/N86208/001/	
/AP/		/3MEQ/ML/	/N86210/001/	
/AP/	/LILLY/	/2MEQ/ML/	/N07865/002/	
	@ LILLY	2MEQ/ML	N07865 002	
AP	STERIS	2MEQ/ML	N86208 001	
AP		3MEQ/ML	N86210 001	

> ADD > PRAVASTATIN SODIUM

> ADD > TABLET; ORAL
> ADD > PRAVACHOL
> ADD > BRISTOL MYERS SQUIBB 10MG¤ N19898 002
> ADD > OCT 31, 1991
> ADD > 20MG¤ N19898 003
> ADD > OCT 31, 1991

PRAZEPAM

CAPSULE; ORAL
PRAZEPAM

/AB/	/PHARM/BASICS/	/5MG/	/N70427/001/	/NOV/06,/1987/
/AB/		/10MG/	/N70428/001/	/NOV/06,/1987/
B*	PHARM BASICS	5MG	N70427 001	NOV 06, 1987
B*		10MG	N70428 001	NOV 06, 1987

PREDNICARBATE

OINTMENT; TOPICAL
DERMATOP
HOECHST ROUSSEL 0.1%¤ N19568 001
SEP 23, 1991

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

/BP/	/CENTRAL/PHARMS/	/25MG/ML/	/N84717/001/	
	@ CENTRAL PHARMS	25MG/ML	N84717 001	
/BP/	/LEMMON/	/25MG/ML/	/N83654/001/	
/BP/		/50MG/ML/	/N85781/001/	
BP	STERIS	25MG/ML	N83654 001	
BP		50MG/ML	N85781 001	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

> ADD > AT	STERIS	EQ 0.11% PHOSPHATE¤	N81043 001	
> ADD >			OCT 24, 1991	
> ADD > AT		EQ 0.9% PHOSPHATE¤	N81044 001	
> ADD >			OCT 24, 1991	

PREDNISONE

TABLET; ORAL
/DELTA-DOME/

/BX/	/MILES/	/5MG/	/N80293/001/	
	@ MILES	5MG	N80293 001	
	PREDNICEN-M			
AB	CENTRAL PHARMS	5MG	N84655 001	
/BX/		/5MG/	/N84655/001/	
	PREDNISONE			
/BX/	/AM/THERAP/	/5MG/	/N89387/001/	/NOV/06,/1986/
/BX/		/10MG/	/N89388/001/	/NOV/06,/1986/
/BX/		/20MG/	/N89389/001/	/NOV/06,/1986/
	@ AM THERAP	5MG	N89387 001	NOV 06, 1986
	@	10MG	N89388 001	NOV 06, 1986
	@	20MG	N89389 001	NOV 06, 1986
> DLT > /BX/	/BARR/	/50MG/	/N86596/001/	
> ADD >	@ BARR	50MG	N86596 001	

PREDNISONE

TABLET; ORAL

	PREDNISONE		
AB	ROXANE	1MG	N87800 001 APR 22, 1982
AB		2.5MG	N87801 001 APR 22, 1982
AB		10MG	N84122 001
AB		20MG	N87342 001
AB		50MG	N84283 001
/RX/		/20MG/	/N17109/001/
/a/		/1MG/	/N87800/001/ /APR/22,/1982/
/a/		/2.5MG/	/N87801/001/ /APR/22,/1982/
/a/		/10MG/	/N84122/001/
a		20MG	N17109 001
/a/		/20MG/	/N87342/001/
/a/		/50MG/	/N84283/001/

PRIMIDONE

TABLET; ORAL

	PRIMIDONE		
>DLT >/AB/	/BOLAR/	/250MG/	/N85052/001/
>ADD > a	BOLAR	250MG	N85052 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	PROCAINAMIDE HCL		
>DLT >/AB/	/BOLAR/	/250MG/	/N83795/001/
>DLT >/AB/		/500MG/	/N84357/001/
>ADD > a	BOLAR	250MG	N83795 001
>ADD > a		500MG	N84357 001

INJECTABLE; INJECTION

	PROCAINAMIDE HCL		
>DLT >/AP/	/WARNER/CHILCOTT/	/100MG/ML/	/N89528/001/ /MAY/03,/1988/
>DLT >/AP/		/500MG/ML/	/N89529/001/ /MAY/03,/1988/
>ADD > a	WARNER CHILCOTT	100MG/ML	N89528 001 MAY 03, 1988
>ADD > a		500MG/ML	N89529 001 MAY 03, 1988

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL		
>DLT >/AB/	/BOLAR/	/1GM/	/N89520/001/ /JAN/15,/1987/
>DLT >			
>ADD > a	BOLAR	1GM	N89520 001 JAN 15, 1987
>ADD >			

	PROCAN SR		
>DLT >/AB/	/PARKE/DAVIS/	/1GM/	/N88489/001/ /JAN/16,/1985/
>DLT >			
>ADD >	PARKE DAVIS	1GM	N88489 001 JAN 16, 1985
>ADD >			

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROCAINE HCL		
/AP/	/CUTTER/	/1%/	/N80415/001/
/AP/		/2%/	/N80415/002/
a	CUTTER	1%	N80415 001
a		2%	N80415 002
/AP/	/LEMMON/	/1%/	/N83535/001/
/AP/		/2%/	/N83535/002/
AP	STERIS	1%	N83535 001
AP		2%	N83535 002

PROCHLORPERAZINE EDISYLATE

/CONCENTRATE;/ORAL/

	/PROCHLORPERAZINE/EDISYLATE/		
	/PHARM/BASICS/	/EQ/10MG/BASE/ML/	/N88598/001/ /OCT/25,/1984/
a	PHARM BASICS	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984

SYRUP; ORAL

	COMPAZINE		
/AA/	/SKF/	/EQ 5MG BASE/5ML/	/N11188/001/
	SKF	EQ 5MG BASE/5ML	N11188 001

	/PROCHLORPERAZINE EDISYLATE/		
/AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N88597/001/ /OCT/25,/1984/
a	PHARM BASICS	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984

PROCHLORPERAZINE MALEATE

TABLET; ORAL

> DLT >	/PROCHLORPERAZINE/			
> DLT >/AB/	/BOLAR/	/EQ 5MG BASE/	/N85580/001/	
> DLT >/AB/		/EQ 10MG BASE/	/N85178/001/	
> DLT >/AB/		/EQ 25MG BASE/	/N85579/001/	
> ADD >	∂ BOLAR	EQ 5MG BASE	N85580 001	
> ADD >	∂	EQ 10MG BASE	N85178 001	
> ADD >	∂	EQ 25MG BASE	N85579 001	
	PROCHLORPERAZINE MALEATE			
/AB/	/DURAMED/	/EQ 5MG BASE/	/N89484/001/ /JAN/20,/1987/	
/AB/		/EQ 10MG BASE/	/N89485/001/ /JAN/20,/1987/	
/AB/		/EQ 25MG BASE/	/N89486/001/ /JAN/20,/1987/	
B*	DURAMED	EQ 5MG BASE	N89484 001 JAN 20, 1987	
B*		EQ 10MG BASE	N89485 001 JAN 20, 1987	
B*		EQ 25MG BASE	N89486 001 JAN 20, 1987	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROMETHAZINE HCL			
/AP/	/LEMMON/	/25MG/ML/	/N83532/001/	
/AP/		/50MG/ML/	/N83532/002/	
AP	STERIS	25MG/ML	N83532 001	
AP		50MG/ML	N83532 002	

SUPPOSITORY; RECTAL

> DLT >	/PROMETHAZINE/HCL/			
> DLT > /BR/	/G/AND/W/	/50MG/	/N87165/001/ /AUG/14,/1987/	
> DLT >				
> ADD >	G AND W	50MG	N87165 001 AUG 14, 1987	
> ADD >				

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL			
∂ ALRA	65MG	N83184 001	
/∂/BANMAX/	/65MG/	/N83184/001/	

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	PROPRANOLOL HCL			
/AP/	/SOLOPAK/	/1MG/ML/	/N70135/001/ /APR/15,/1986/	
	∂ SOLOPAK	1MG/ML	N70135 001 APR 15, 1986	

SOLUTION; ORAL

	PROPRANOLOL HCL			
/AA/	/PHARM/BASICS/	/20MG/5ML/	/N71984/001/ /MAR/03,/1989/	
/AA/		/40MG/5ML/	/N71985/001/ /MAR/03,/1989/	
	∂ PHARM BASICS	20MG/5ML	N71984 001 MAR 03, 1989	
	∂	40MG/5ML	N71985 001 MAR 03, 1989	
/AA/	/ROXANE/	/20MG/5ML/	/N70979/001/ /MAY/15,/1987/	
/AA/		/40MG/5ML/	/N70690/001/ /MAY/15,/1987/	
	ROXANE	20MG/5ML	N70979 001 MAY 15, 1987	
		40MG/5ML	N70690 001 MAY 15, 1987	

TABLET; ORAL

	PROPRANOLOL HCL			
> DLT >/AB/	/BOLAR/	/10MG/	/N70378/001/ /MAR/19,/1987/	
> DLT >				
> DLT >/AB/		/20MG/	/N70379/001/ /MAR/19,/1987/	
> DLT >				
> DLT >/AB/		/40MG/	/N70380/001/ /MAR/19,/1987/	
> DLT >				
> DLT >/AB/		/60MG/	/N70381/001/ /MAR/19,/1987/	
> DLT >				
> DLT >/AB/		/80MG/	/N70382/001/ /MAR/19,/1987/	
> DLT >				
> ADD >	∂ BOLAR	10MG	N70378 001 MAR 19, 1987	
> ADD >				
> ADD >	∂	20MG	N70379 001 MAR 19, 1987	
> ADD >				
> ADD >	∂	40MG	N70380 001 MAR 19, 1987	
> ADD >				
> ADD >	∂	60MG	N70381 001 MAR 19, 1987	
> ADD >				
> ADD >	∂	80MG	N70382 001 MAR 19, 1987	
> ADD >				

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

/AB/	/DURAMED/	/40MG/	/N70308/001/ /SEP/09,/1985/
/AB/		/60MG/	/N70309/001/ /OCT/01,/1986/
/AB/		/80MG/	/N70310/001/ /SEP/09,/1985/
B*	DURAMED	40MG	N70308 001 SEP 09, 1985
B*		60MG	N70309 001 OCT 01, 1986
B*		80MG	N70310 001 SEP 09, 1985
/AB/	/MARTEC/	/10MG/	/N70120/001/ /AUG/06,/1985/
/AB/		/20MG/	/N70121/001/ /AUG/06,/1985/
/AB/		/40MG/	/N70122/001/ /AUG/06,/1985/
/AB/		/60MG/	/N70123/001/ /OCT/29,/1986/
/AB/		/80MG/	/N70124/001/ /AUG/06,/1985/
AB	SCHERING	10MG	N70120 001 AUG 06, 1985
AB		20MG	N70121 001 AUG 06, 1985
AB		40MG	N70122 001 AUG 06, 1985
AB		60MG	N70123 001 OCT 29, 1986
AB		80MG	N70124 001 AUG 06, 1985
/AB/	/SUPERPHARM/	/40MG/	/N71517/001/ /JUN/08,/1988/
/AB/		/80MG/	/N71518/001/ /JUN/08,/1988/
	∂ SUPERPHARM	40MG	N71517 001 JUN 08, 1988
	∂	80MG	N71518 001 JUN 08, 1988

PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE

TABLET, EXTENDED RELEASE; ORAL

	SELDANE-D		
	MERRELL DOW	120MG;60MG¤	N19664 001 AUG 19, 1991

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

KALI DUPHAR	30MG	N89572 001 NOV 27, 1990
/PUREPAC/	/30MG/	/N89572/001/ /NOV/27,/1990/

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

/AP/	/LEMMON/	/100MG/ML/	/N83760/001/
AP	STERIS	100MG/ML	N83760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

/AA/	/CHELSEA/	/25MG/	/N85231/001/
	∂ CHELSEA	25MG	N85231 001
/AA/	/RICHLYN/	/25MG/	/N80808/001/
	RICHLYN	25MG	N80808 001

QUAZEPAM

TABLET; ORAL

DORAL

BAKER CUMMINS	7.5MG	N18708 003 FEB 26, 1987
	15MG	N18708 001 DEC 27, 1985
/DORMALIN/ /BAKER/CUMMINS/	/7.5MG/	/N18708/003/ /FEB/26,/1987/
	/15MG/	/N18708/001/ /DEC/27,/1985/

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N16768 002

QUINIDINE GLUCONATE

/TABLET;/ORAL/
/QUINACT/
/BERLEX/ /266MG/ /N85978/001/
/400MG/ /N86099/001/
∂ BERLEX 266MG N85978 001
∂ 400MG N86099 001

TABLET, EXTENDED RELEASE; ORAL
/QUINATIME/
/AB/ /BOLAR/ /324MG/ /N87448/001/
∂ BOLAR 324MG N87448 001
QUINIDINE GLUCONATE
/AB/ /ROXANE/ /324MG/ /N88431/001/
/JAN/06,/1984/
∂ ROXANE 324MG N88431 001
JAN 06, 1984

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
/AB/ /VANGARD/ /200MG/ /N87909/001/
/JUL/13,/1982/
∂ VANGARD 200MG N87909 001
JUL 13, 1982

QUINORA
/AB/ /KEY/PHARMS/ /200MG/ /N83576/001/
∂ KEY PHARMS 200MG N83576 001

RAMIPRIL

CAPSULE; ORAL
ALTACE
HOECHST ROUSSEL 1.25MG¤ N19901 001
JAN 28, 1991
2.5MG¤ N19901 002
JAN 28, 1991
5MG¤ N19901 003
JAN 28, 1991
10MG¤ N19901 004
JAN 28, 1991

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC IN PLASTIC CONTAINER
/GLAXO/ /EQ/50MG/BASE/100ML/ /N19593/001/
/DEC/17,/1986/
∂ GLAXO EQ 50MG BASE/100ML N19593 001
DEC 17, 1986
EQ 1MG BASE/ML¤ N19593 002
SEP 27, 1991

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA
BP DANBURY 50MG N80907 001
/∂/ /50MG/ /N80907/001/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /WHITE/TOWNE/PAULSEN/ /0.1MG/ /N80723/001/
/BP/ /0.25MG/ /N80723/002/
∂ WHITE TOWNE PAULSEN 0.1MG N80723 001
∂ 0.25MG N80723 002
/1MG/ /N80723/003/
∂ 1MG N80723 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
AP ABBOTT 10MG/ML¤ N71618 001
FEB 28, 1991
AP 15MG/ML¤ N71619 001
FEB 28, 1991
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 30MG/100ML¤ N71438 001
JAN 22, 1991

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
/AA/ /WYETH/AYERST/ /100MG/ /N86390/001/
∂ WYETH AYERST 100MG N86390 001

CAPSULE; ORAL

SECOBARBITAL SODIUM

/AA/ /WYETH/AYERST/ /100MG/ /N86390/001/

@ WYETH AYERST 100MG N86390 001

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT CLAY PARK 2.5% N89996 001 JAN 10, 1991

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

/AP/ /LYPHOMED/ /50MG/VIAL/ /N70031/001/ /JAN/17,/1985/

@ LYPHOMED 50MG/VIAL N70031 001 JAN 17, 1985

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

>DLT >/AB/ /BOLAR/ /25MG/ /N86898/002/ /MAR/02,/1982/

>DLT >

>ADD > @ BOLAR 25MG N86898 002 MAR 02, 1982

>ADD >

SUCCIMER

CAPSULE; ORAL

CHEMET

MCNEIL 100MG% N19998 002 JAN 30, 1991

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

>DLT >/AB/ /BOLAR/ /500MG/ /N85053/001/

>ADD > @ BOLAR 500MG N85053 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

COTRIM

/AP/ /STERIS/ /80MG/ML;16MG/ML/ /N71556/001/ /DEC/17,/1987/

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>ADD > AP GENSIA 80MG/ML;16MG/ML% N73303 001 OCT 31, 1991

>ADD >

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP STERIS 80MG/ML;16MG/ML N71556 001 DEC 17, 1987

SUSPENSION; ORAL

COTRIM PEDIATRIC

AB LEMMON 200MG/5ML;40MG/5ML N70028 001 OCT 29, 1985

/SULFAMETHOXAZOLE AND TRIMETHOPRIM/

/AB/ /PLANTEX/ /200MG/5ML;40MG/5ML/ /N70028/001/ /OCT/29,/1985/

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

/AB/ /PHARM/BASICS/ /400MG;80MG/ /N70203/001/ /NOV/08,/1985/

/AB/ /800MG;160MG/ /N70204/001/ /NOV/08,/1985/

B* PHARM BASICS 400MG;80MG N70203 001 NOV 08, 1985

B* 800MG;160MG N70204 001 NOV 08, 1985

AB ROXANE 400MG;80MG% N72768 001 AUG 30, 1991

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB ROXANE LABS 800MG;160MG% N72769 001 AUG 30, 1991

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

AT LEMMON 15% N88718 001 SEP 19, 1985

/VAGITROL/

/AT/ /LEMMON/ /15%/ /N88718/001/ /SEP/19,/1985/

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

>ADD > KABI 500MG N07073 002 APR 06, 1983

>ADD >

>DLT >/AB/ /PHARMACIA/ /500MG/ /N07073/002/ /APR/06,/1983/

>DLT >

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL

>DLT>	/SULFASALAZINE/			
>DLT> /BE/	/BOLAR/	/500MG/	/N88052/001/ /MAY/24,/1983/	
>DLT>				
>ADD>	∂ BOLAR	500MG	N88052 001 MAY 24, 1983	
>ADD>				

SULFISOXAZOLE

TABLET; ORAL

SOXAZOLE

∂ ALRA			
/∂/BANMAX/	500MG	/500MG/	N80366 001 /N80366/001/

SULINDAC

TABLET; ORAL

SULINDAC

AB	GENEVA	150MG¤	N72712 001 AUG 30, 1991
AB		200MG¤	N72713 001 AUG 30, 1991
AB	LEDERLE	150MG¤	N73261 001 SEP 06, 1991
AB		200MG¤	N73262 001 SEP 06, 1991
AB	MUTUAL PHARM	150MG¤	N72050 001 APR 17, 1991
AB		200MG¤	N72051 001 APR 17, 1991
AB	WARNER CHILCOTT	150MG¤	N72710 001 MAR 25, 1991
AB		200MG¤	N72711 001 MAR 25, 1991

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

MALLINCKRODT	N/A¤	N19981 001 JUN 10, 1991

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

>ADD>	SANDOZ	7.5MG¤	N18163 003 OCT 25, 1991
>ADD>			

TEMAZEPAM

>DLT>/AB/	/BOLAR/	/15MG/	/N70383/001/ /MAR/23,/1987/
>DLT>			
>DLT>/AB/		/30MG/	/N70384/001/ /MAR/23,/1987/
>DLT>			
>ADD>	∂ BOLAR	15MG	N70383 001 MAR 23, 1987
>ADD>			
>ADD>	∂	30MG	N70384 001 MAR 23, 1987
>ADD>			
/AB/	/PHARM/BASICS/	/15MG/	/N70489/001/ /JUL/07,/1986/
/AB/		/30MG/	/N70490/001/ /JUL/07,/1986/
B*	PHARM BASICS	15MG	N70489 001 JUL 07, 1986
B*		30MG	N70490 001 JUL 07, 1986

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

JOHNSON RW	0.8%¤	N19964 001 FEB 21, 1991

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

/AO/	/LEMMON/	/100MG/ML/	/N84401/001/
/AO/		/200MG/ML/	/N84401/002/
AO	STERIS	100MG/ML	N84401 001
AO		200MG/ML	N84401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

/AO/	/LEMMON/	/100MG/ML/	/N83667/001/
/AO/		/200MG/ML/	/N83667/002/
AO	STERIS	100MG/ML	N83667 001
AO		200MG/ML	N83667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AO/	/LEMMON/	/25MG/ML/	/N85490/001/
/AO/		/50MG/ML/	/N85490/002/
/AO/		/100MG/ML/	/N83595/003/
AO	STERIS	25MG/ML	N85490 001
AO		50MG/ML	N85490 002
AO		100MG/ML	N83595 003

THEOPHYLLINE

CAPSULE; ORAL

/SOMOPHYLLIN-T/

/BX/	/FISONS/	/100MG/	/N87155/001/ /FEB/25,/1985/
/BX/		/200MG/	/N87155/002/ /FEB/25,/1985/
/BX/		/250MG/	/N87155/003/ /FEB/25,/1985/
	a FISONS	100MG	N87155 001 FEB 25, 1985
	a	200MG	N87155 002 FEB 25, 1985
	a	250MG	N87155 003 FEB 25, 1985

THEOPHYLLINE

/BX/	/SCHERER/	/100MG/	/N84731/002/ /NOV/07,/1986/
/BX/		/200MG/	/N84731/001/ /NOV/07,/1986/
/BX/		/250MG/	/N84731/003/ /NOV/07,/1986/
	a SCHERER	100MG	N84731 002 NOV 07, 1986
	a	200MG	N84731 001 NOV 07, 1986
	a	250MG	N84731 003 NOV 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

/THEOPHYL-SR/

/BC/	/JOHNSON/RW/	/125MG/	/N86480/001/ /FEB/08,/1985/
	a JOHNSON RW	125MG	N86480 001 FEB 08, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

/THEOPHYLLINE/

/BC/	/CENTRAL/PHARMS/	/125MG/	/N88654/001/ /FEB/12,/1985/
/BC/		/250MG/	/N88689/001/ /FEB/12,/1985/
	a CENTRAL PHARMS	125MG	N88654 001 FEB 12, 1985
	a	250MG	N88689 001 FEB 12, 1985

THEOPHYLLINE-SR

/BC/	/SCHERER/	/300MG/	/N88255/001/ /JUN/12,/1986/
	a SCHERER	300MG	N88255 001 JUN 12, 1986

TABLET; ORAL

/THEOCLEAR-100/

/BD/	/CENTRAL/PHARMS/	/100MG/	/N85353/002/
	a CENTRAL PHARMS	100MG	N85353 002

/THEOCLEAR-200/

/BD/	/CENTRAL/PHARMS/	/200MG/	/N85353/001/
	a CENTRAL PHARMS	200MG	N85353 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/LEMMON/	/100MG/ML/	/N83534/001/
/AP/		/200MG/ML/	/N83534/002/
/AP/	/LYPHOMED/	/100MG/ML/	/N80509/001/
	a LYPHOMED	100MG/ML	N80509 001
AP	STERIS	100MG/ML	N83534 001
AP		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

>DLT >/AB/	/BOLAR/	/10MG/	/N88412/001/		
>DLT >			/SEP/12,/1983/		
>DLT >/AB/		/15MG/	/N88345/001/		
>DLT >			/JUL/28,/1983/		
>DLT >/AB/		/25MG/	/N88296/001/		
>DLT >			/JUL/28,/1983/		
>DLT >/AB/		/50MG/	/N88323/001/		
>DLT >			/JUL/28,/1983/		
>DLT >/AB/		/100MG/	/N88284/001/		
>DLT >			/AUG/25,/1983/		
>DLT >/AB/		/150MG/	/N88410/001/		
>DLT >			/MAR/05,/1984/		
>DLT >/AB/		/200MG/	/N88381/001/		
>DLT >			/MAR/14,/1984/		
>ADD >	∂ BOLAR	10MG	N88412 001		
>ADD >			SEP 12, 1983		
>ADD >	∂	15MG	N88345 001		
>ADD >			JUL 28, 1983		
>ADD >	∂	25MG	N88296 001		
>ADD >			JUL 28, 1983		
>ADD >	∂	50MG	N88323 001		
>ADD >			JUL 28, 1983		
>ADD >	∂	100MG	N88284 001		
>ADD >			AUG 25, 1983		
>ADD >	∂	150MG	N88410 001		
>ADD >			MAR 05, 1984		
>ADD >	∂	200MG	N88381 001		
>ADD >			MAR 14, 1984		
/AB/	/ROXANE/	/10MG/	/N88663/001/		
			/MAR/15,/1984/		
/AB/		/25MG/	/N88664/001/		
			/MAR/15,/1984/		
/AB/		/50MG/	/N88665/001/		
			/MAR/15,/1984/		
/AB/		/100MG/	/N89048/001/		
			/FEB/26,/1985/		
	∂ ROXANE	10MG	N88663 001		
			MAR 15, 1984		
	∂	25MG	N88664 001		
			MAR 15, 1984		
	∂	50MG	N88665 001		
			MAR 15, 1984		
	∂	100MG	N89048 001		
			FEB 26, 1985		

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

/AB/	/AM/THERAP/	/1MG/	/N71884/001/
			/AUG/12,/1987/
/AB/		/2MG/	/N71885/001/
			/AUG/12,/1987/
/AB/		/10MG/	/N71887/001/
			/AUG/12,/1987/
	∂ AM THERAP	1MG	N71884 001
			AUG 12, 1987
	∂	2MG	N71885 001
			AUG 12, 1987
	∂	10MG	N71887 001
			AUG 12, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL

/AA/	/PACO/	/EQ 5MG BASE/ML/	/N71939/001/
			/DEC/16,/1988/
		/EQ 1MG BASE/ML/	/N71917/001/
			/SEP/20,/1989/
	∂ PACO	EQ 5MG BASE/ML	N71939 001
			DEC 16, 1988
		EQ 1MG BASE/ML	N71917 001
			SEP 20, 1989

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

SYNTEX

>ADD >			
>ADD >			
>ADD >			
>ADD >		250MG‡	N19979 002
>ADD >			OCT 31, 1991

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

>DLT >/AB/	/BOLAR/	/5MG/	/N72269/001/	/MAR/14,/1989/
>DLT >				
>DLT >/AB/		/10MG/	/N72270/001/	/MAR/14,/1989/
>DLT >				
>DLT >/AB/		/20MG/	/N72271/001/	/MAR/14,/1989/
>DLT >				
>ADD >	ə BOLAR	5MG	N72269 001	MAR 14, 1989
>ADD >				
>ADD >	ə	10MG	N72270 001	MAR 14, 1989
>ADD >				
>ADD >	ə	20MG	N72271 001	MAR 14, 1989
>ADD >				
AB	DANBURY	5MG¤	N72917 001	JUL 31, 1991
AB		10MG¤	N72918 001	JUL 31, 1991
AB		20MG¤	N72919 001	JUL 31, 1991
/AB/	/PHARM/BASICS/	/5MG/	/N72001/001/	/JAN/10,/1989/
/AB/		/10MG/	/N72002/001/	/JAN/10,/1989/
/AB/		/20MG/	/N72003/001/	/JAN/10,/1989/
B*	PHARM BASICS	5MG	N72001 001	JAN 10, 1989
B*		10MG	N72002 001	JAN 10, 1989
B*		20MG	N72003 001	JAN 10, 1989

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 10MG BASE/ML¤	N63080 001 APR 30, 1991
AP		EQ 10MG BASE/ML¤	N63112 001 APR 30, 1991
AP		EQ 40MG BASE/ML¤	N63111 001 APR 30, 1991
AP		EQ 40MG BASE/ML¤	N63161 001 MAY 29, 1991

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	LEDERLE	EQ 10MG BASE/ML¤	N63113 001 APR 26, 1991
AP		EQ 40MG BASE/ML¤	N63117 001 APR 26, 1991
AP		EQ 40MG BASE/ML¤	N63118 001 JUL 29, 1991

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

>DLT >/AB/	/BOLAR/	/100MG/	/N70242/001/ /AUG/01,/1986/
>DLT >			
>DLT >/AB/		/250MG/	/N70243/001/ /AUG/01,/1986/
>DLT >			
>DLT >/AB/		/500MG/	/N70244/001/ /AUG/01,/1986/
>DLT >			
>ADD >	ə BOLAR	100MG	N70242 001 AUG 01, 1986
>ADD >			
>ADD >	ə	250MG	N70243 001 AUG 01, 1986
>ADD >			
>ADD >	ə	500MG	N70244 001 AUG 01, 1986
>ADD >			
/AB/	/CHELSEA/	/100MG/	/N70285/001/ /JAN/09,/1986/
/AB/		/250MG/	/N70286/001/ /JAN/09,/1986/
/AB/		/500MG/	/N70287/001/ /JAN/09,/1986/
B*	CHELSEA	100MG	N70285 001 JAN 09, 1986
B*		250MG	N70286 001 JAN 09, 1986
B*		500MG	N70287 001 JAN 09, 1986
/AB/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/
/AB/		/250MG/	/N70168/001/ /APR/02,/1986/
/AB/		/500MG/	/N70169/001/ /APR/02,/1986/
B*	PHARM BASICS	100MG	N71355 001 JAN 11, 1988
B*		250MG	N70168 001 APR 02, 1986
B*		500MG	N70169 001 APR 02, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

		∂ ALRA	500MG	N86141 001
	/∂/	/BANMAX/	/500MG/	/N86141/001/
>_DLT_>/AB/		/BOLAR/	/250MG/	/N89110/001/
>_DLT_>				/MAY/29,/1987/
>_DLT_>/AB/			/500MG/	/N89111/001/
>_DLT_>				/MAY/29,/1987/
>_ADD_>		∂ BOLAR	250MG	N89110 001
>_ADD_>				MAY 29, 1987
>_ADD_>		∂	500MG	N89111 001
>_ADD_>				MAY 29, 1987

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

>_DLT_>/AB/		/BOLAR/	/50MG/	/N71112/001/
>_DLT_>				/NOV/17,/1986/
>_DLT_>/AB/			/100MG/	/N71113/001/
>_DLT_>				/NOV/17,/1986/
>_ADD_>		∂ BOLAR	50MG	N71112 001
>_ADD_>				NOV 17, 1986
>_ADD_>		∂	100MG	N71113 001
>_ADD_>				NOV 17, 1986
	/AB/	/CHELSEA/	/50MG/	/N70568/001/
	/AB/		/100MG/	/OCT/10,/1986/
				/N70569/001/
	B*	CHELSEA	50MG	/OCT/10,/1986/
				N70568 001
	B*		100MG	OCT 10, 1986
				N 0569 001
	AB	MYLAN	50MG¤	OCT 10, 1986
				N71405 001
	AB		100MG¤	FEB 27, 1991
				N71406 001
	/AB/	/PHARM/BASICS/	/50MG/	FEB 27, 1991
				/N70491/001/
	/AB/		/100MG/	/APR/29,/1987/
				/N70492/001/
	B*	PHARM BASICS	50MG	/APR/29,/1987/
				N70491 001
	B*		100MG	APR 29, 1987
				N70492 001
				APR 29, 1987

TRETINOIN

GEL; TOPICAL

RETIN-A

/AT/	/JOHNSON/RW/	/0.01%/	/N17519/003/

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

RHONE POULENC RORER 55UGM/INH¤ N19798 001 JUL 11, 1991

CREAM; TOPICAL

/KENAC/

/AT/	/NMC/	/0.025%/	/N87797/001/
			/JUN/07,/1982/
/AT/		/0.1%/	/N87798/001/
			/JUN/04,/1982/

TRIAMCINOLONE ACETONIDE

AT	G AND W	0.025%¤	N89797 001 MAY 31, 1991
AT		0.1%¤	N89798 001 MAY 31, 1991
AT	NMC	0.025%	N87797 001 JUN 07, 1982
AT		0.1%	N87798 001 JUN 04, 1982
/AT/	/PHARM/BASICS/	/0.025%/	/N88094/001/
			/SEP/01,/1983/
/AT/		/0.1%/	/N88095/001/
			/SEP/01,/1983/
/AT/		/0.5%/	/N88096/001/
			/SEP/01,/1983/
	∂ PHARM BASICS	0.025%	N88094 001 SEP 01, 1983
	∂	0.1%	N88095 001 SEP 01, 1983
	∂	0.5%	N88096 001 SEP 01, 1983

/GEL;/TOPICAL/

/ARISTOGEL/

	/LEDERLE/	/0.1%/	/N83380/001/
	∂ LEDERLE	0.1%	N83380 001

OINTMENT; TOPICAL

ARISTOCORT A

/AT/	/LEDERLE/	/0.5%/	/N88781/001/
			/OCT/05,/1984/
	∂ LEDERLE	0.5%	N88781 001 OCT 05, 1984

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

/AT/	/KENAC/ /NMC/	/0.1%/	/N87799/001/ /JUN/07,/1982/	
AT	NMC	0.1%	N87799 001 JUN 07, 1982	
/AT/	/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/	
/AT/		/0.1%/	/N88091/001/ /SEP/01,/1983/	
/AT/		/0.5%/	/N88092/001/ /SEP/01,/1983/	
	@ PHARM BASICS	0.025%	N88090 001 SEP 01, 1983	
	@	0.1%	N88091 001 SEP 01, 1983	
	@	0.5%	N88092 001 SEP 01, 1983	

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

TRIAMCINOLONE DIACETATE

/BP/	/LEMMON/	/40MG/ML/	/N85529/001/	
BP	STERIS	40MG/ML	N85529 001	

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

>DLT>	/BP/ /BOLAR/	/4MG/	/N83462/001/	
>ADD>	@ BOLAR	4MG	N83462 001	

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

>DLT>	/AB/	/BOLAR/	/EQ 1MG BASE/	/N85975/001/ /JUN/23,/1988/	
>DLT>			/EQ 2MG BASE/	/N85976/001/ /JUN/23,/1988/	
>DLT>	/AB/		/EQ 5MG BASE/	/N85973/001/ /JUN/23,/1988/	
>DLT>	/AB/		/EQ 10MG BASE/	/N88710/001/ /JUN/23,/1988/	
>ADD>	@ BOLAR		EQ 1MG BASE	N85975 001 JUN 23, 1988	
>ADD>	@		EQ 2MG BASE	N85976 001 JUN 23, 1988	
>ADD>	@		EQ 5MG BASE	N85973 001 JUN 23, 1988	
>ADD>	@		EQ 10MG BASE	N88710 001 JUN 23, 1988	
	/AB/	/DURAMED/	/EQ 1MG BASE/	/N88967/001/ /APR/23,/1985/	
	/AB/		/EQ 2MG BASE/	/N88968/001/ /APR/23,/1985/	
	/AB/		/EQ 5MG BASE/	/N88969/001/ /APR/23,/1985/	
	/AB/		/EQ 10MG BASE/	/N88970/001/ /APR/23,/1985/	
	B*	DURAMED	EQ 1MG BASE	N88967 001 APR 23, 1985	
	B*		EQ 2MG BASE	N88968 001 APR 23, 1985	
	B*		EQ 5MG BASE	N88969 001 APR 23, 1985	
	B*		EQ 10MG BASE	N88970 001 APR 23, 1985	

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HCL

>DLT>	/AA/	/BOLAR/	/2MG/	/N85117/001/
>DLT>	/AA/		/5MG/	/N85105/001/
>ADD>	@ BOLAR		2MG	N85117 001
>ADD>	@		5MG	N85105 001

TRIMEPRAZINE TARTRATE

SYRUP; ORAL

	TEMARIL					
/AA/	/HERBERT/	/EQ 2.5MG BASE/5ML/	/N11316/003/			
	HERBERT	EQ 2.5MG BASE/5ML	N11316 003			
	TRIMEPRAZINE TARTRATE					
/AA/	/PHARM BASICS/	/EQ 2.5MG BASE/5ML/	/N88285/001/ /APR/11,/1985/			
	∂ PHARM BASICS	EQ 2.5MG BASE/5ML	N88285 001 APR 11, 1985			

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TRIMETHOBENZAMIDE HCL					
/AP/	/SOLOPAK/	/100MG/ML/	/N89043/001/ /APR/04,/1986/	> ADD >	AB	N73229 001 OCT 29, 1991
	∂ SOLOPAK	100MG/ML	N89043 001 APR 04, 1986	> ADD >	SCHERER	250MG

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

	TRIMIPRAMINE MALEATE					
/AA/	/PHARM BASICS/	/EQ 25MG BASE/	/N71283/001/ /DEC/08,/1987/			
/AA/		/EQ 50MG BASE/	/N71284/001/ /DEC/08,/1987/			
/AA/		/EQ 100MG BASE/	/N71285/001/ /DEC/08,/1987/			
B*	PHARM BASICS	EQ 25MG BASE	N71283 001 DEC 08, 1987			
B*		EQ 50MG BASE	N71284 001 DEC 08, 1987			
B*		EQ 100MG BASE	N71285 001 DEC 08, 1987			

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	TRIPROLIDINE HCL					
/AA/	/DANBURY/	/2.5MG/	/N85094/001/			
	DANBURY	2.5MG	N85094 001			
/AA/	/VITARINE/	/2.5MG/	/N85610/001/			
	∂ VITARINE	2.5MG	N85610 001			

TRISULFAPYRIMIDINES

SUSPENSION; ORAL

	SULFOSE					
/AA/	/WYETH AYERST/	/500MG/5ML/	/N80013/002/			
	∂ WYETH AYERST	500MG/5ML	N80013 002			

TABLET; ORAL

	SULFOSE					
/AA/	/WYETH AYERST/	/500MG/	/N80013/001/			
	∂ WYETH AYERST	500MG	N80013 001			

VALPROIC ACID

CAPSULE; ORAL

	VALPROIC ACID					
/AP/	/SCHERER/	/250MG/	/N73229/001/ /OCT/29,/1991/	> ADD >	AB	N73229 001 OCT 29, 1991
	∂ SCHERER	250MG	N73229 001 OCT 29, 1991	> ADD >	SCHERER	250MG

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	CALAN					
/AP/	/SEARLE/	/2.5MG/ML/	/N18925/001/ /MAR/30,/1984/			
	∂ SEARLE	2.5MG/ML	N18925 001 MAR 30, 1984			
	VERAPAMIL HCL					
/AP/	/SOLOPAK/	/2.5MG/ML/	/N70697/001/ /JUL/31,/1987/			
	∂ SOLOPAK	2.5MG/ML	N70697 001 JUL 31, 1987			

TABLET; ORAL

	VERAPAMIL HCL					
B*	CHELSEA	80MG	N70421 001 SEP 17, 1986			
B*		120MG	N70422 001 SEP 17, 1986			
/BX/		/80MG/	/N70421/001/ /SEP/17,/1986/			
/BX/		/120MG/	/N70422/001/ /SEP/17,/1986/			

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR					
	KNOLL	120MG	N19152 003 MAR 06, 1991			

VITAMIN A PALMITATE

CAPSULE; ORAL

AA	∂ MILES	EQ 50,000 UNITS BASE	N80972 001

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

> DLT >	∂ BOLAR	2MG	N86123 001 AUG 17, 1982
> DLT >		2.5MG	N86120 001 AUG 17, 1982
> DLT >		5MG	N86119 001 AUG 17, 1982
> DLT >		7.5MG	N86118 001 AUG 17, 1982
> DLT >		10MG	N86122 001 AUG 17, 1982
> ADD >	∂ BOLAR	2MG	N86123 001 AUG 17, 1982
> ADD >	∂	2.5MG	N86120 001 AUG 17, 1982
> ADD >	∂	5MG	N86119 001 AUG 17, 1982
> ADD >	∂	7.5MG	N86118 001 AUG 17, 1982
> ADD >	∂	10MG	N86122 001 AUG 17, 1982

XYLOSE

POWDER; ORAL

XYLO-PFAN

AA	ADRIA	25GM/BOT	N17605 001

XYLOSE

AA	LYNE	25GM/BOT	N18856 001 MAR 26, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

/TYLENOL/ /MCNEIL/	/120MG/ /650MG/	/N17756/002/ /N17756/001/
ə MCNEIL	120MG	N17756 002
ə	650MG	N17756 001

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE /ə/XTTRIUM/	/2%/	/N19422/001/ /DEC/17,/1985/
XTTRIUM	2%	N19422 001 DEC 17, 1985
MICRODERM JOHNSON AND JOHNSON	4%¤	N72255 001 APR 15, 1991

SPONGE; TOPICAL

MICRODERM JOHNSON AND JOHNSON	4%¤	N72295 001 FEB 28, 1991

CLOTRIMAZOLE

CREAM; TOPICAL

MYCELEX MILES	1%¤	N18183 002 APR 01, 1991

SOLUTION; TOPICAL

MYCELEX MILES	1%¤	N18181 002 APR 01, 1991

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOBROM GENEVA	6MG;120MG¤	N70770 001 SEP 30, 1991

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE COPLEY	25MG¤	N88900 002 FEB 12, 1988

HYDROCORTISONE

/OINTMENT;/TOPICAL/ /HC/(HYDROCORTISONE)/ /C/AND/M/	/0.5%/	/N80481/001/
ə C AND M	0.5%	N80481 001

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL COLD AND SINUS WHITEHALL	200MG;30MG	N19771 001 SEP 19, 1989
/COADVIL/ /WHITEHALL/	/200MG;30MG/	/N19771/001/ /SEP/19,/1989/

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

NOVOLIN R NOVO NORDISK	100UNITS/ML¤	N19938 001 JUN 25, 1991

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

NOVOLIN 70/30 NOVO NORDISK	30UNITS/ML;70UNITS/ML¤	N19991 001 JUN 25, 1991

INSULIN PORK

INJECTABLE; INJECTION

INSULIN /NOVO/NORDISK/	/40/UNITS/ML/	/N17926/001/
ə NOVO NORDISK	40 UNITS/ML	N17926 001

INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN N
NOVO NORDISK 100UNITS/ML¤ N19959 001
JUL 01, 1991

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN
/NOVO NORDISK/ /40/UNITS/ML/ /N17998/001/
@ NOVO NORDISK 40 UNITS/ML N17998 001

INSULIN ZINC SUSP BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN L
NOVO NORDISK 100UNITS/ML¤ N19965 001
JUN 25, 1991

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 7
JOHNSON RW 2%¤ N17450 002
FEB 15, 1991

SUPPOSITORY; VAGINAL
MONISTAT 7
JOHNSON RW 100MG¤ N18520 002
FEB 15, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE

>ADD> TABLET, EXTENDED RELEASE; ORAL
>ADD> SUDAFED 12 HOUR
>ADD> BURROUGHS WELLCOME 120MG¤ N73585 001
>ADD> OCT 31, 1991

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

INJECTABLE; INJECTION
HESPAN
DUPONT MERCK
PHARM — 6GM/100ML;0.9GM/100ML — N890105
APR 04, 1991

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

INJECTABLE; INJECTION
PENTASPAN
DUPONT MERCK
PHARM — 10GM/100ML;0.9GM/100ML — N890104
APR 04, 1991

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALPHA-GALACTOSIDASE A TRADE: CC-GALACTOSIDASE	TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY. (FABRY'S DISEASE).	DAVID H. CALHOUN, PH.D. CITY COLLEGE OF NEW YORK
GENERIC: ANTIVENOM (CROTALIDAE) PURIFIED (AVIAN) TRADE: NOT ESTABLISHED	TREATMENT OF ENVENOMATION BY POISONOUS SNAKES BELONGING TO THE CROTALIDAE FAMILY.	OPHIDIAN PHARMA
GENERIC: BOTULINUM TOXIN TYPE A TRADE: OCULINUM*/**	TREATMENT OF STRABISMUS ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF BLEPHAROSPASM ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF CERVICAL DYSTONIA.	ALLERGAN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: CLOSTRIDIUM BOTULINUM TYPE F NEUROTOXIN TRADE: NOT ESTABLISHED	TREATMENT OF SPASMODIC TORTICOLLIS.	PORTON PRODUCTS LIMITED
GENERIC: CHIMERIC M-T412 (HUMAN-MURINE) IGG MONOCLONAL ANTI-CD4 ANTIBODY TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	CENTOCOR, INC
GENERIC: CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TRADE: NOT ESTABLISHED	USE IN CONJUNCTION WITH GANCICLOVIR SODIUM FOR THE TREATMENT OF CYTOMEGALOVIRUS PNEUMONIA IN BONE MARROW TRANSPLANT PATIENTS.	MILES, INC
GENERIC: EPOETIN ALPHA (RECOMBINANT-HUMAN) TRADE: EPOGEN*/**	TREATMENT OF ANEMIA ASSOCIATED WITH HIV INFECTION OR HIV TREATMENT. [TREATMENT OF AZT-INDUCED ANEMIA IN HIV INFECTED PATIENTS.*/**] [DEC 31, 1997]	AMGEN
GENERIC: FILGRASTIM TRADE: NEUPOGEN	TREATMENT OF PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) WHO, IN ADDITON, ARE AFFLICTED WITH CYTOMEGALOVIRUS RETINITIS (CMV RETINITIS) AND ARE BEING TREATED WITH GANCICLOVIR.	AMGEN, INC
GENERIC: HUMAN MONOCLONAL ANTIBODY AGAINST HEPATITIS B VIRUS TRADE: NOT ESTABLISHED	PROPHYLAXIS OF HEPATITIS B REINFECTION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION SECONDARY TO END-STAGE CHRONIC HEPATITIS B INFECTION.	SANDOZ PHARMACEUTICALS CORPORATION
GENERIC: INSULIN-LIKE GROWTH FACTOR-1 TRADE: MYOTROPHIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	CEPHALON, INC
GENERIC: INTERFERON (RECOMBINANT, BETA) TRADE: R-IFN-BETA	SYSTEMIC TREATMENT OF METASTATIC RENAL CELL CARCINOMA. SYSTEMIC TREATMENT OF CUTANEOUS T-CELL LYMPHOMA. SYSTEMIC TREATMENT OF CUTANEOUS MALIGNANT MELANOMA. INTRALESIONAL AND/OR SYSTEMIC TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA.	BIOGEN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: INTERLEUKIN-1 ALPHA, HUMAN RECOMBINANT TRADE: NOT ESTABLISHED	FOR THE PROMOTION OF EARLY ENGRAFTMENT IN BONE MARROW TRANSPLANTATION. FOR HEMATOPOIETIC POTENTIATION IN APLASTIC ANEMIA.	IMMUNEX CORPORATION
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	SYNERGEN, INC
GENERIC: INTERLEUKIN-3, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	PROMOTION OF ERYTHROPOIESIS IN DIAMOND-BLACKFAN ANEMIA (CONGENITAL PURE CELL RED APLASIA).	IMMUNEX CORPORATION
GENERIC: MONOCLONAL ANTIBODY PM-81 TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA.	MEDAREX, INC
GENERIC: MUCOID EXOPOLYSACCHARIDE PSEUDOMONAS HYPERIMMUNE GLOBULIN TRADE: MEPIG	TREATMENT OF PULMONARY INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS.	UNIVAX BIOLOGICS, INC
GENERIC: MYELIN TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	AUTOIMMUNE, INC
GENERIC: POLY I: POLY $C_{12}U$ TRADE: AMPLIGEN	TREATMENT OF RENAL CELL CARCINOMA.	HEM RESEARCH, INC
GENERIC: RECOMBINANT HUMAN DEOXYRIBONUCLEASE (RHDNASE) TRADE: NOT ESTABLISHED	TO REDUCE MUCOUS VISCOSITY AND ENABLE CLEARANCE OF AIRWAY SECRETIONS IN PATIENTS WITH CYSTIC FIBROSIS.	GENENTECH, INC
GENERIC: RECOMBINANT SECRETORY LEUCOCYTE PROTEASE INHIBITOR TRADE: NOT ESTABLISHED	TREATMENT OF CONGENITAL ALPHA-1 ANTITRYPSIN DEFICIENCY. TREATMENT OF CYSTIC FIBROSIS.	SYNERGEN, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: RICIN (BLOCKED) CONJUGATED MURINE MONOCLONAL ANTIBODY (ANTI-B4) TO B CELL (CD 19) TRADE: NOT ESTABLISHED	FOR THE EX-VIVO PURGING OF LEUKEMIC CELLS FROM THE BONE MARROW OF NON-T CELL ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS WHO ARE IN COMPLETE REMISSION.	IMMUNOGEN, INC
GENERIC: RICIN (BLOCKED) CONJUGATED MURINE MONOCLONAL ANTIBODY (N901) TO CD56 POSITIVE CELLS TRADE: NOT ESTABLISHED	TREATMENT OF SMALL CELL LUNG CANCER.	IMMUNOGEN, INC
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOICATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA. [MAR 5, 1998]	IMMUNEX
GENERIC: SDZ MSL-109 TRADE: NOT ESTABLISHED	PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN PATIENTS UNDERGOING SOLID ORGAN TRANSPLANTATION.	SANDOZ PHARMACEUTICALS CORP
GENERIC: THYMOSIN ALPHA-1 TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	ALPHA 1 BIOMEDICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALGLUCERASE TRADE: CEREDASE*/**	REPLACEMENT THERAPY IN PATIENTS WITH GAUCHER'S DISEASE TYPE I. [APR 5, 1998]	GENZYME
GENERIC: BERACTANT TRADE: SURVANTA*/**	PREVENTION OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998] TREATMENT OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998]	ROSS
GENERIC: CALCIUM GLUCONATE GEL TRADE: H-F GEL	EMERGENCY TOPICAL TREATMENT OF HYDROGEN FLUORIDE (HYDROFLUORIC ACID) BURNS.	LTR PHARMACEUTICALS, INC
GENERIC: CYCLOSPORINE 2% OPHTHALMIC OINTMENT TRADE: SANDIMMUNE	TREATMENT OF PATIENTS AT HIGH RISK OF GRAFT REJECTION FOLLOWING PENETRATING KERATOPLASTY. USE IN CORNEAL MELTING SYNDROMES OF KNOWN OR PRESUMED IMMUNOLOGIC ETIOPATHOGENESIS INCLUDING MOOREN'S ULCER.	SANDOZ PHARMACEUTICALS CORP
GENERIC: CYSTEAMINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	WARNER-LAMBERT COMPANY
GENERIC: DEFEROXAMINE AND DEXTRAN TRADE: BIO-RESCUE	TREATMENT OF ACUTE IRON POISONING.	BIOMEDICAL FRONTIERS, INC
GENERIC: DESMOPRESSIN ACETATE TRADE: DDAVP HIGH CONCENTRATION	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RORER PHARMACEUTICAL CORP
GENERIC: DRONABINOL TRADE: MARINOL	STIMULATION OF APPETITE AND PREVENTION OF WEIGHT LOSS IN PATIENTS WITH A CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	UNIMED, INC
GENERIC: ETIDRONATE DISODIUM TRADE: DIDRONEL	PREVENTION OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION. TREATMENT OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION.	MGI PHARMA, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: FLUDARABINE PHOSPHATE TRADE: FLUDARA*/**	TREATMENT OF REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. [APR 18, 1998]	BERLEX
GENERIC: FOSPHENYTOIN TRADE: NOT ESTABLISHED	ACUTE TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS OF THE GRAND MAL TYPE.	WARNER-LAMBERT COMPANY
GENERIC: GALLIUM NITRATE TRADE: GANITE*/**	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY. [JAN 17, 1998]	FUJISAWA PHARM
GENERIC: GENTAMICIN IMPREGNATED PMMA BEADS ON SURGICAL WIRE TRADE: SEPTOPAL	TREATMENT OF CHRONIC OSTEOMYELITIS OF POST-TRAUMATIC, POSTOPERATIVE OR HEMATOGENOUS ORIGIN.	E. MERCK, DARMSTADT
GENERIC: HISTRELIN TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE INTERMITTENT PORPHYRIA, HEREDITARY COPROPORPHYRIA, AND VARIEGATE PORPHYRIA.	KARL E. ANDERSON, M.D. UNIVERSITY OF TEXAS
GENERIC: IDARUBICIN HCL TRADE: IDAMYCIN	TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN PEDIATRIC PATIENTS.	ADRIA
GENERIC: KETOCONAZOLE TRADE: NOT ESTABLISHED	FOR USE WITH CYCLOPORIN A TO DIMINISH THE NEPHROTOXICITY INDUCED BY CYCLOSPORIN IN ORGAN TRANSPLANTATION.	PHARMEDIC COMPANY
GENERIC: L-LEUCOVORIN CALCIUM TRADE: ISOVORIN	USE IN CONJUNCTION WITH HIGH-DOSE METHOTREXATE IN THE TREATMENT OF OSTEOSARCOMA.	LEDERLE LABORATORIES
GENERIC: LODOXAMIDE TROMETHAMINE TRADE: ALOMIDE	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC
GENERIC: METRONIDAZOLE TRADE: METROGEL	TREATMENT OF PERIORAL DERMATITIS.	CURATEK PHARMACEUTICALS
GENERIC: NIFEDIPINE TRADE: NOT ESTABLISHED	TREATMENT OF INTERSTITIAL CYSTITIS.	JONATHAN FLEISCHMANN, M.D. CLEVELAND METROHEALTH MEDICAL CENTER

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: OFLOXACIN TRADE: NOT ESTABLISHED	TREATMENT OF BACTERIAL CORNEAL ULCERS.	ALLERGAN, INC
GENERIC: OM 401 TRADE: DREPANOL	PROPHYLACTIC TREATMENT OF SICKLE CELL DISEASE.	OMEX INTERNATIONAL, INC
GENERIC: OXANDROLONE TRADE: OXANDRIN	ADJUNCTIVE THERAPY FOR AIDS PATIENTS SUFFERING FROM HIV-WASTING SYNDROME.	GYNEX, INC
GENERIC: PENTOSTATIN TRADE: NIPENT*/**	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. TREATMENT OF HAIRY CELL LEUKEMIA. (SINGLE AGENT TREATMENT FOR ADULT PATIENTS WITH ALPHA-INTERFERON-REFRACTORY HAIRY CELL LEUKEMIA.*/** [OCT 11, 1998])	PARKE-DAVIS
GENERIC: POLOXAMER 331 TRADE: PROTOX	INITIAL THERAPY OF TOXOPLASMOSIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYDROME (AIDS).	BURROUGHS WELLCOME COMPANY
GENERIC: RECOMBINANT HUMAN SUPEROXIDE DISMUTASE TRADE: NOT ESTABLISHED	PREVENTION OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE NEONATES WEIGHING LESS THAN 1500 GMS.	BIO TECHNOLOGY GENERAL CORP
GENERIC: RIBAVIRIN TRADE: VIRAZOLE	TREATMENT OF HEMORRHAGIC FEVER WITH RENAL SYNDROME.	ICN PHARMACEUTICALS, INC
GENERIC: SUCCIMER TRADE: CHEMET*/**	TREATMENT OF LEAD POISONING IN CHILDREN.*/** [JAN 30, 1998] TREATMENT OF MERCURY INTOXICATION.	MCNEIL
GENERIC: SUCRALFATE TRADE: NOT ESTABLISHED	TREATMENT OF ORAL ULCERATIONS AND DYSPHAGIA IN PATIENTS WITH EPIDERMOLYSIS BULLOSA.	NASKA PHARMCAL CO
GENERIC: TESTOSTERONE PROPIONATE TRADE: NOT ESTABLISHED	TREATMENT OF VULVAR DYSTROPHIES.	STAR PHARMACEUTICALS, INC
GENERIC: TESTOSTERONE SUBLINGUAL TRADE: NOT ESTABLISHED	TREATMENT OF CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY IN BOYS.	GYNEX, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: TIRATRICOL TRADE: TRIACANA	USE IN COMBINATION WITH LEVO-THYROXINE TO SUPPRESS THYROID STIMULATING HORMONE (TSH) IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER WHO ARE INTOLERANT TO ADEQUATE DOSES OF LEVO-THYROXINE ALONE.	MEDGENIX GROUP
GENERIC: TOREMIFENE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: URSODEOXYCHOLIC ACID TRADE: ACTIGALL	MANAGEMENT OF THE CLINICAL SIGNS AND SYMPTOMS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS.	CIBA GEIGY
GENERIC: URSODEOXYCHOLIC ACID TRADE: URSOFALK	TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS.	INTERFALK U.S., INC
GENERIC: 3,4 DIAMINOPYRADINE TRADE: DYNAMINE	TREATMENT OF HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE I (CHARCOT-MARIE-TOOTH DISEASE).	MAYO CLINIC
GENERIC: 6-METHYLENANDROSTA-1,4-DIENE-3,17-DIONE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: 566C80 TRADE: NOT ESTABLISHED	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP) IN HIGH-RISK, HIV-INFECTED PATIENTS DEFINED BY ONE OR BOTH OF THE FOLLOWING CRITERIA: (1) A HISTORY OF ONE OR MORE EPISODES OF PCP, (2) A PERIPHERAL CD4+ (T4 HELPER/INDUCER) LYMPHOCYTE COUNT LESS THAN OR EQUAL TO 200/MM^3.	BURROUGHS WELLCOME COMPANY

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1991 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 278, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ESTROGENS, CONJUGATED (TABLET)	AUG 21, 1991	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CARBAMAZEPINE SUSPENSION; ORAL	200MG/5ML	89 P-0399/CP	GUIDELINES	NEW DOSAGE FORM	APPROVED MAY 16, 1991
CLOBETASOL PROPIONATE LOTION; TOPICAL	0.05%	90 P-0198/ CP1	KROSS	NEW DOSAGE FORM	APPROVED MAR 14, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/VIAL	90 P-0250/ CP1	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	200MG/VIAL	90 P-0250/ CP2	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/VIAL	90 P-0250/ CP3	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	1GM/VIAL	90 P-0250/ CP4	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYTARABINE INJECTABLE; INJECTION	20MG/ML (100ML/CONTAINER)	86 P-0428/ CP005	ADRIA	NEW DOSAGE FORM	APPROVED OCT 28, 1991
DOPAMINE HYDROCHLORIDE INJECTABLE; INJECTION	5MG/ML	90 P-0137/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 10, 1991

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (25ML/VIAL)	91 P-0041/ CP1	ADRIA	NEW STRENGTH	APPROVED MAY 22, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.067MG/24HR	90 P-0125/ CP1	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.084MG/24HR	90 P-0125/ CP2	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	90 P-0436/ CP1	KV	NEW DOSAGE FORM	APPROVED OCT 23, 1991
PANCURONIUM BROMIDE INJECTABLE; INJECTION	0.1MG/ML	91 P-0006/ CP1	LYPHOMED	NEW STRENGTH	APPROVED OCT 28, 1991
TECHNETIUM TC99 MEDRONATE KIT INJECTABLE; INJECTION	N/A	91 P-0040/ CP1	ABARIS	NEW STRENGTH	APPROVED OCT 28, 1991
TERFENADINE CAPSULE; ORAL	60MG	91 P-0087 CP1	ARTHUR A. CHECCHI	NEW DOSAGE FORM	APPROVED OCT 28, 1991

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
FUROSEMIDE INJECTABLE; INJECTION	1MG/ML	90 P-0313/ CP1	LYPHOMED	NEW STRENGTH	DENIED OCT 28, 1991

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW INDICATION

I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS.
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION.
I-64	PREVENTION OF SUPRAVENTRICULAR ARRHYTHMIAS.

REFERENCES
PATENT USE CODE

U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20089 001	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997			
	20089 002	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997			
	20057 003	ALGLUCERASE; CEREDASE				NCE	APR 05, 1996
						ODE	APR 05, 1998
	18276 001	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 002	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 003	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 004	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
			3980789	SEP 14, 1993			
	19926 001	ALTRETAMINE; HEXALEN				ODE	DEC 26, 1997
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	4105783	OCT 26, 1995			
	18700 001	AMRINONE LACTATE; INOCOR	4072746	APR 23, 1998	U-7	NCE	JUL 31, 1994
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	20032 001	BERACTANT; SURVANTA	4397839	AUG 10, 2000		NCE	JUL 01, 1996
>ADD>	18709 001	CAPTOPRIL; CAPOZIDE 25/15				I-63	OCT 24, 1994
>ADD>	18709 002	CAPTOPRIL; CAPOZIDE 25/25				I-63	OCT 24, 1994
>ADD>	18709 003	CAPTOPRIL; CAPOZIDE 50/25				I-63	OCT 24, 1994
>ADD>	18709 004	CAPTOPRIL; CAPOZIDE 50/15				I-63	OCT 24, 1994
	19856 001	CARBIDOPA; SINEMET CR	4900755	MAY 23, 2006			
			4832957	MAY 23, 2006			
			3830827	AUG 20, 1991			
						NDF	MAY 30, 1994
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	4312860	NOV 23, 2001		NC	AUG 02, 1993
	17920 002	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 003	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 004	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 005	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 24, 1998		NCE	DEC 31, 1995
	19082 001	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19082 002	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	19082 003	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960779	OCT 02, 2007			
			3652762	MAR 28, 1991		NDF	MAR 28, 1994
>ADD>	20154 002	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20154 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20154 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20154 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20155 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20155 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20155 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20155 006	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20156 001	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
>ADD>	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
>ADD>	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	OCT 20, 2004		NCE	MAR 07, 1996
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 004	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
>ADD>	19080 001	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
>DLT>	19080 001	ESTAZOLAM; PROSOM	3987052	OCT 19, 1993			
>ADD>	19080 002	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
>DLT>	19080 002	ESTAZOLAM; PROSOM	3987052	OCT 19, 1993			
>ADD>	19081 002	ESTRADIOL; ESTRADERM				I-62	OCT 24, 1994
>ADD>	19081 003	ESTRADIOL; ESTRADERM				I-62	DEC 24, 1994
	19653 001	ETHINYL ESTRADIOL; ORTHO CYCLEN-21	4027019	MAY 31, 1996		NC	DEC 29, 1992
	19653 002	ETHINYL ESTRADIOL; ORTHO CYCLEN-28	4027019	MAY 31, 1996		NC	DEC 29, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18922 002	ETODOLAC; LODINE	4076831	FEB 28, 1995	U-45		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
	18922 003	ETODOLAC; LODINE	4076831	FEB 28, 1995	U-45		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 26, 1996
	19834 002	FELODIPINE; PLENDIL	4262611	APR 28, 1998		NCE	JUL 26, 1996
>ADD>	18830 001	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
>ADD>	18830 003	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
>ADD>	18830 004	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	19949 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 002	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 003	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19950 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 1999		NCE	APR 18, 1996
						ODE	APR 18, 1998
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		NCE	DEC 29, 1992
>ADD>	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
>DLT>	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	JUN 15, 1999			
>ADD>	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
>DLT>	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	JUN 15, 1999			
	20068 001	FOSCARNET SODIUM; FOSCAVIR				NCE	SEP 27, 1996
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
	19961 002	GALLIUM NITRATE; GANITE	4529593	JUL 16, 2002	U-49	NCE	JAN 17, 1996
						ODE	JAN 17, 1998
>ADD>	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
>DLT>	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	OCT 28, 2003		NCE	DEC 17, 1995
>ADD>	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
>DLT>	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	OCT 28, 2003		NCE	DEC 17, 1995
>ADD>	19784 001	IBUPROFEN; RUFEN				NDF	SEP 19, 1992
	19580 001	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19580 002	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19546 001	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995
	19546 002	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 002	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 003	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 004	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 002	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 003	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 004	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	19425 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	20035 001	LEVAMISOLE HYDROCHLORIDE; ERGAMISOL	4584305	JUN 19, 2004	U-42	NCE	JUN 18, 1995
	20088 001	LEVONORGESTREL; NORPLANT SYSTEM	3850911	NOV 26, 1991		NP	DEC 10, 1993
	19753 001	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
	19753 002	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
	19753 003	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
	19886 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	18612 001	NICOTINE POLACRILEX; NICORETTE	3901248	AUG 26, 1992		NCE	JAN 13, 1994
	19684 001	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
	19684 002	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
	19684 003	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
	19508 001	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
	19508 002	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
	19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002			
			4146719	MAR 27, 1998		NDF	JUN 17, 1994
>ADD>	19735 001	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
>DLT>	19735 001	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000			
>ADD>	19735 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
>DLT>	19735 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000			
>ADD>	19735 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
>DLT>	19735 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000			
	19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004		NCE	JUL 31, 1995
	19810 001	OMEPRAZOLE; PRILOSEC	4255431	MAR 10, 2000		I-57	JUN 12, 1994
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	NCE	JAN 04, 1996
			4695578	SEP 22, 2004			
>ADD>	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		NCE	OCT 31, 1996
>ADD>			3962432	JUN 08, 1993	U-53		
>ADD>	20122 001	PENTOSTATIN; NIPENT	3923785	DEC 02, 1992		ODE	OCT 11, 1998
>ADD>						NCE	OCT 11, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18631 001	PENTOXIFYLLINE; TRENTAL	3737433	APR 03, 1997		NCE	AUG 30, 1994
	19456 001	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19456 002	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19797 001	POLYETHYLENE GLYCOL 3350; NULYTELY				NP	APR 22, 1994
>ADD>	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
>ADD>	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1997	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		NCE	OCT 02, 1994
>ADD>	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	3878217	APR 15, 1994		NC	AUG 19, 1994
	19901 001	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 002	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 003	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 004	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19863 001	SERMORELIN ACETATE; GEREF	4703035	MAY 14, 2002	U-47	NCE	DEC 28, 1995
			4517181	MAY 14, 2002		NCE	DEC 28, 1995
	19998 002	SUCCIMER; CHEMET				NCE	JAN 30, 1996
						ODE	JAN 30, 1998
	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51	NC	JUN 10, 1994
>ADD>	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995
>DLT>	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	JUN 05, 2001		NCE	DEC 21, 1995
>ADD>	19785 002	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995
>DLT>	19785 002	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	JUN 05, 2001		NCE	DEC 21, 1995
>ADD>	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003		NCE	OCT 31, 1996
>ADD>			4051141	SEP 27, 1994			
>ADD>	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003		NCE	OCT 31, 1996
>ADD>			4051141	SEP 27, 1994			
	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT				NR	JUL 11, 1994

*U.S. Government Printing Office: 1991 — 312-211/40004